FORM = BASELINE

CONTEXT **INVSITE SUBJNO**

Baseline

< V:4 ><V:5> Patient Initials: __INITIALS Patient Number: PATID<V:10> CONCANTINATION OF INVSITE & SUBJNO

Minnesota Living with Heart Failure

Instructions: These questions concern how your heart failure (heart condition) has prevented you from living as you wanted during the last month. The items listed below describe different ways some people are affected. If you are sure an item does not apply to you or is not related to your heart failure then circle 0 (meaning "No") and go onto the next item. If an item does apply to you, then circle the number rating of how much it prevented you from living as you wanted. Remember to think about ONLY THE LAST MONTH. LWHFQUES (TYPE 3)

Did your heart failure prevent you from living as you wanted during the LAST MONTH by:

	No	Very Little			-	Very Much
SWELL <esrate> 1. causing swelling in your ankles, legs, etc?</esrate>	= 0	1 = 1	2 = 2	3 = 3	4 = 4	5 = 5
2. making your working around the house or yard difficult?	0	1	2	3	4	5
FRIENDS <esrate> 3. making your relating to or doing things with your friends difficult?</esrate>	0	1	2	3	4	5
4. making you sit or lie down to rest during the day?	0	1	2	3	4	5
ENERGY <esrate> 5. making you tired, fatigued, or low on energy?</esrate>	0	1	2	3	4	5
6. making your working to earn a living difficult?	0	1	2	3	4	5
WALKC <esrate> 7. making your walking or climbing stairs difficult?</esrate>	0	1	2	3	4	5
BREATH <esrate> 8. making you short of breath?</esrate>	0	1	2	3	4	5
SLEEP < ESRATE > 9. making your sleeping well at night difficult?	0	1	2	3	4	5
0. making EAT SESPATE the foods you like?	0	1	2	3	4	5
AWAY <esrate> 1. making your going places away from home difficult?</esrate>	0	1	2	3	4	5
SEX <esrate> 2. making your sexual activities difficult?</esrate>	0	1	2	3	4	5
HOBBIE <esrate> 3. making your recreational pastimes, sports, or hobbies difficult?</esrate>	0	1	2	3	4	5
REMEM <esrate> 4. making it difficult for you to concentrate or remember things?</esrate>	0	1	2	3	4	5
EFFECT <esrate> 5. giving you side effects from medications?</esrate>	0	1	2	3	4	5
WORRY <esrate> 6. making you worry?</esrate>	0	1	2	3	4	5
DEPRS <esrate> 7. making you feel depressed?</esrate>	0	1	2	3	4	5
COST <esrate> 8. costing you money for medical care?</esrate>	0	1	2	3	4	5
9. making you feel a loss of self-control in your life?	0	1	2	3	4	5
STAY <esrate> O. making you stay in a hospital?</esrate>	0	1	2	3	4	5
BURDEN <esrate> 21. making you feel you are a burden to your family or friends?</esrate>	0	1	2	3	4	5

05/28/2004



Baseline Physician Assessment

Patient Number: _____ - ___ patient # Patient Initials: ___ ___

Heart Failure Clinical Assessment Symptoms
Does the patient have any of the following? SYMPTOMS (TYPE3)
No Yes No Yes No Yes Fatigue: 0 1 Dyspnea: 0 1 At rest FREST < ZYESNO> At rest DREST < ZYESNO> Walking in room DWALKRM < ZYESNO> Walking < 1 block DWALKBK < ZYESNO> DWALKBK DWALK
Orthopnea (check only one): 1 Needs only 1 pillow 2 Occasional orthopnea with 1 pillow ORTHOP <esmsr> 3 Needs 2 pillows most of the time 4 Needs 3 pillows most of the time 5 Needs 4 pillows most of the time (sitting up)</esmsr>
GIDIST <eswitn> Gastrointestinal distress (check only one):</eswitn>
Heart Failure Clinical Assessment—Physical Exam
Heart rate (supine): bpm
Blood pressure manual cuff (supine): Systolic / Systolic / Systolic mmHg PHYSDAY <esinhs></esinhs>
Blood pressure manual cuff (standing after 3 minutes): WT <f:9:3> WTUNIT <zwgtu> WEIGHT: RESP Respiratory rate: <1:2> Blood pressure manual cuff (standing after 3 minutes): STSYSBP STDIABP 4I:3> mmHg mmHg</zwgtu></f:9:3>
TEMPUNIT <ztmpu> Temperature:TEMP <f:9:3> [] C2 F</f:9:3></ztmpu>
Jugular venous pulsation (cm above the right otrium): 1 < 8 2 8 -12 3 12-16 4 >16 0 Cannot measure RALES < ESRALE> Rales: 0 None 1 < 1/3 2 1/3 - 2/3 3 > 2/3 S3 < ZYESNO>
Auscultation: S3: 0 No 1 Yes ESTPZPAS Estimated P2-PAS: 1 < 40 2 40-50 3 51-60 4 > 60 <espas> HEPMEG <eshepa></eshepa></espas>
Hepatomegaly (check only one): 0 Absent 1 2-4 finger breadths HEPREFLX <zyesno> Hepatojugular reflux: 0 No 1 Yes</zyesno>
ASCITES <esacit> Ascites (check only one): 0 None 1 Trace 2 Moderate 3 Massive PEREDMA <esedma> Peripheral edema (check only one): 0 0 1 1+ 2 2+ 3 3+ 4 4+</esedma></esacit>
EXTREM <esextr> Extremities (check only one): 1 Cool 2 Lukewarm 3 Warm</esextr>
Valsalva maneuver (check only one): 1 Normal 2 Absent overshoot 3 Square-wave 4 Uncertain OR 5 Not applicable
CLINPRO <espro> Clinical profile (check only one): 1 Dry/warm 2 Wet/warm 3 Dry/cold 4 Wet/cold</espro>



Baseline Physician Assessment

Patient Number: _____ - ___ patient # Patient Initials: ___ ___

Heart Failure C	linical Asses	sment-	_Estimo	ite of He	emodyı	namic S	tatus
Right atrial pressure (n	RAP <esrap> nmHg) (check only one):</esrap>	: 1 < 8	2 8 -12	3 13 - 16	4 >16		HEMSTAT (TYPE 3)
Certainty of assessr	APCERT <escert> nent (check only one):</escert>	1 1 not very su		3 3	4 4	5 5 — very sure	CROSSDT <date></date>
Pulmonary capillary w	WEDGPF edge pressure (mm	RES <eswi nHg) (check</eswi 	EDG> only one): 1] < 12 2	12 - 22 [3 23 - 30	4 >30
Certainty of assessr	GCERT <escert> nent (check only one):</escert>	1 1 not very su	2 2	3 3	4 4	5 5 — very sure	
CAR Cardiac index (L/min •	DINDX <escar> m²) (check only one):</escar>	1 < 1.8	2 1.8 - 2	.2 3 2.3	- 2.5 4	> 2.5	
Certainty of assessn	RDCERT <escert> nent (check only one):</escert>	1 1 not very su	2 2	3 3	4 4	5 5 very sure	
Physician Estim	ate of Likeli	hood d	of Death	over ne	ext 6 m	onths	
Check only one:	□ 0 - 25% □ 26 - 50% □ 51 - 75% □ 76 - 100%		Tl	nis is not e	entered		
Physician Estim	ate of Read	missio	n over r	next 6 m	onths		
Check only one:	☐ 0 - 25% ☐ 26 - 50% ☐ 51 - 75% ☐ 76 - 100%		Т	his is not	entered		
Signature (Phys	ician who perf	formed	assessm	ent)			
, ,				PHYSDAY <	ESINHS>		SIGNATUR (TYPE 4)
SIGTYPE <zsigty> Investigator's signature: Study Coordinator</zsigty>	SIGNANS <zyes></zyes>	· 1 = YES,	IF SIGNED	Date perform	ed:	_/ SIGDT < month	DATE>year



	Patient Number:	site # patient #	Patient Initials:
Demographics		The state of the s	
Date of birth:/	ATE> _/	GENDE (03/OCT/1930) Sex: [R <zsex> DEMOG (TYPE 1) Male 2 Female</zsex>
Race (check only one):	2 Black 3 Asian 4 Hispanic ZHGTU> cm	5 Native American 98	Other (specify): <u>RACETX <v:40></v:40></u>
Randomization			
Enrolling hospital admission date a	nd time:/ HOSADMDT < D	ATE> HOSAD	MTM RANDO (TYPE 1) TIME> 23:59
Was the patient transferred from a TRANSFER <zyesno></zyesno>	NoYes → If Yes, date of admission:	:/ TRNADMDT <	DATE>
	CC <zyesno> on and exclusion criteria? 0 No</zyesno>	1 Yes	
Randomization date and time:	RANDODT <date></date>	RANDOTM < DATETIM	E>
RANPAC <zy [<="" pac?="" patient="" randomized="" th="" to="" was=""><th>YESNO></th><th></th><th></th></zy>	YESNO>		
Socioeconomic Inform	ation		
LIVEALN < ZYESNO: Does the patient live alone? RESIDNCE < ESRES> Patient's residence (check only one): EDUCATN < ESED> Education (highest level completed): INSURANC < ESINS>	O No	hool 5 High school	SOCIO (TYPE 1)
INCOME <esinc> Household income level (US\$): RESUSORD <esresu> Resuscitation orders (check only one):</esresu></esinc>	O None Private Medicare Medicaid Private and Medicare Medicare and Medicaid < S Medicare and Medicaid A 25,000 Attempt cardiopulmonary resuscitations] 50-74,999	99
Resuscitation orders (check only only).	Attempt cardiopulmonary resuscitors Do not attempt cardiopulmonary resuscitors.	ition but do not intubate	
Clinical History			
Estimated date of initial diagnosis of	of heart failure:/	DATE>	CLINHIS1 (TYPE 1)
Number of hospitalizations within p	prior 12 months (specify): <1:2>		
Date of last hospital admission:	LSTADMDT <date> day month year - LSTLVDT <date></date></date>		
Date of last LVEF:	day / / year -	_	
Value of last LVEF: EF <1:3> % (recor	rd whole number)		
Quantitative method of LV function (check only one):	LVMETH <eslv> ionuclide ventriculogram</eslv>	ılar angiography 3 Echoo	cardiogram



Patient Number: _____ Patient Initials: _____

Clinical History (continued)							
Primary etiology of heart failure (rank up ETIOHF < ESHF > 1 = Alcoholic ETIOHFRK < I:1>					CLINHIS		2) PS
2 = Cytotoxic drug therapy <i:1></i:1>		= Hypertensive	<u><i:1></i:1></u> <i:1></i:1>	7 = Peripartum 8 =Valvular	<u><i:1></i:1></u> <i:1></i:1>		
3 = Familial < <u>I:1></u>		= Idiopathic = Ischemic	<i:1></i:1>	9 = Other/uncer			
3 - I diffind) _ischemic	<u> </u>	y _ Omery oncer	<u> </u>	•	
Does the patient have a documented his			ving?		CLINHIS3	`	
DOCHIST <eshist> Ischemic heart disease:</eshist>	CHISYN <	TVECNOS I	16 = Gout:			No	Yes 1
1 =Angina pectoris	0	1	17 = Hepatic d	lisease:		0	1
2 = Myocardial infarction (MI)	0	1	18 = Hyperten	sion:		0	1
3 = Percutaneous transluminal			Cerebrov	ascular disease:			
coronary intervention (PTCI)	0	1	19 = TIA			0	1
4 = Coronary artery bypass graft (CABG)	0	1	20 = Stroke			0	1
Valvular heart disease:			Arrhythm	ias:			
5 = Primary tricuspid regurgitation	0	1	21 = Atrial fib	orillation		0	1
6 = Mitral stenosis	0	1	22 = Sustaine	ed ventricular tachycardi	a	0	1
7 = Primary mitral regurgitation	0	1	23 = Torsade:	s de pointe		0	1
8 = Aortic stenosis	0	1	24 = Ventricul	lar fibrillation		0	1
9 =Aortic regurgitation	0	1	25 = Cardiac	arrest/Rhythm unknown		0	1
= Peripheral vascular disease:	0		26 = Implantal	ble cardiac defibrillato	r:	0	1
Chronic obstructive pulmonary disease:	0	1	27 = Pacemak	er placement:		0	1
= Chronic steroid use:	0	1	28 = Maligna n	ncy:		0	1
= Diabetes:	0	1	29 = Depressio	on (treated with prescription	medications):	0	1
14 = Insulin dependent	0	1					
15 = Controlled by oral agents	0	1					
CIGSMOK <essmok> Cigarette smoking (check only one):</essmok>	L Current	2 Quit <	6 months ago	3 Quit ≥ 6 month		VHIS4 (T Never	YPE 1)
HRTTRAN <eshrt></eshrt>	Ineligib	e 2 Active	evaluation	3 No evaluation	olanned		
RENAL <esren></esren>	_	of creatinine > 3		2 History of chror		0 Noithar	
	_		.5 mg/ul	I history of chilor	iic didiysis 1	_ I Velillei	
Left Heart Catheterizatio	n Res	ults	LOTOTH	OT <daţe></daţe>		LOTOTIA	IA ZVEC
Date of last left heart catheterization be		lomization:	dov /	nonth year	OR 🗓	LSTCTHN Not applica	able
STENLM < Vessels with > 70% stenosis (check all that a	apply): 1	LM I LAD NLAD <zyes></zyes>		RCA NRCA <zyes></zyes>	LHC	CATH (T	YPE 1)
ECG (Record results of ECG close	st to tim	e of random	ization.)				
Date and time:/	OATE>	year -	ECGTM <d< td=""><td>OATETIME></td><td>Е</td><td>CG (TYP</td><td>PE 3)</td></d<>	OATETIME>	Е	CG (TYP	PE 3)
Rate: bpm	R	HYTHM <esr< td=""><td>HY></td><td></td><td></td><td></td><td></td></esr<>	HY>				
Rhythm (check only one): Sinus bradycare 2 Atrial fibrillation	n/flutter		_	us tachycardia			
ABNRE Specific abnormalities (check all that apply):	BBB <zyi RBBB AB</zyi 	±S> □ LBBB □ NLBBB <zyes< td=""><td>ABNNA <zy Not applicab</zy </td><td>ES> le</td><td></td><td></td><td></td></zyes<>	ABNNA <zy Not applicab</zy 	ES> le			



Patient Number: _____ Patient Initials: _____

Current N	leaications (include a	II medications patient was taking prio	r to hospitalization.)	
ACE inhibitor:			ACE1 (TYI	
ACE inhibitor:	No → If No, specify red ANGIO < ZVES	ison (check all that apply): 1 Angioedema, anaphylaxis, neutropenia	`	,
	COUGH <zyes></zyes>			
ACE <zyesn< th=""><th></th><th>•</th><th></th><th></th></zyesn<>		•		
		Renal artery stenosis		
		Renal dysfunction		
	SYMP <zyes></zyes>			
		1 Other adverse events such as taste disturbate	nce. rash. and aastrointest	inal upset
	OTHE CETES		A(Total daily dose:	CE2 (TYPE 3)
	1 Yes → If Yes:	Benazepril BENAZ <zyes></zyes>	BENAZDS <f:9:3></f:9:3>	
	i les Fillles.	Captopril CAPTO <zyes></zyes>	CAPTODS <f:9:3></f:9:3>	19
		I Enalapril ENALA <zyes></zyes>	ENALADS <f:9:3></f:9:3>	
		Fosinopril FOSINO < ZYES>	FOSINODS <f:9:3>m</f:9:3>	
		LISINO <zyes></zyes>	LISINODS <f:9:3> m</f:9:3>	
		1 Quinapril QUINA <zyes></zyes>	QUINADS <f:9:3> m</f:9:3>	
		Ramipril RAMI <zyes></zyes>	RAMIDS <f:9:3></f:9:3>	
		Trandolapril TRANDO <zyes></zyes>	TRANDODS <f:9:3>m</f:9:3>	
		Other (specify): OTHACESP < V:60>	OTHACEDS <f:9:3< th=""><th></th></f:9:3<>	
		OTHACE <zyes></zyes>		ŭ
Angiotensin II a	ntagonist :		Total daily dose:	ODIG (TYPE 3)
	No 1 Yes → If Yes:	1 Candesartan CANDE <zyes></zyes>	GIAMPEDG FOR	ng
	2 110 2 100 11 100	Losartan LOSAR <zyes></zyes>		ng
	ANGIOT <zyesno></zyesno>	1 Valsartan VALSAR <zyes></zyes>	VALSARDS <f:9:3> m</f:9:3>	
		1 Other (specify): OTHANGSP <v:60></v:60>	OTHANGDS <f:9:3></f:9:3>	
		OTHANG <zyes></zyes>		
	DIGOXIN <zyesno></zyesno>			ng
Digoxin:		pecify total dose and frequency:	1QD 2QO	D 98 Other
Digoxin:		pecify total dose and frequency:	IQD ZQOI	D 98 Other SESFO>
	① No 1 Yes → If Yes, s	_	I QD 2 QOI DIGFQ Total daily dose:	D 98 Other CESFQ> DIUR1 (TYPE 3)
Diuretic:		Bumetanide BUMETA <zyes></zyes>	I QD 2 QOI DIGFO Total daily dose: BUME <u>TADS <f:9:3></f:9:3></u> m	D 98 Other CESFQ> DIUR1 (TYPE 3)
	① No 1 Yes → If Yes, s	Bumetanide BUMETA <zyes> Ethacrynic acid ETHACR <zyes></zyes></zyes>	I QD 2 QOI DIGFO Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m</f:9:3></f:9:3>	D 98 Other CESFQ> DIUR1 (TYPE 3) ng
Diuretic:	 No	Bumetanide BUMETA <zyes> Ethacrynic acid ETHACR <zyes> Furosemide FUROSE <zyes></zyes></zyes></zyes>	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m</f:9:3></f:9:3></f:9:3>	D
Diuretic:	 No	Bumetanide BUMETA <zyes> Ethacrynic acid ETHACR <zyes></zyes></zyes>	I QD 2 QOI DIGFO Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m</f:9:3></f:9:3>	D
Diuretic:	No	Bumetanide BUMETA <zyes> Ethacrynic acid ETHACR <zyes> Furosemide FUROSE <zyes> Torsemide TORSE <zyes></zyes></zyes></zyes></zyes>	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m TORSEDS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3>	D
Diuretic:	No	Bumetanide BUMETA <zyes> Ethacrynic acid ETHACR <zyes> Furosemide FUROSE <zyes> Torsemide TORSE <zyes> Other (specify): OTHDILSP <v:60></v:60></zyes></zyes></zyes></zyes>	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m TORSEDS <f:9:3> m OTHDILDS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D
Diuretic:	No I Yes → If Yes, sNo I Yes → If Yes:DIULOOP <zyesno></zyesno>	Bumetanide BUMETA <zyes> Ethacrynic acid ETHACR <zyes> Furosemide FUROSE <zyes> Torsemide TORSE <zyes> Other (specify): OTHDILSP <v:60></v:60></zyes></zyes></zyes></zyes>	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m TORSEDS <f:9:3> m OTHDILDS <f:9:3> m Total daily dose: AMILODS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D 93 Other CESFO> DIUR1 (TYPE 3) ag ag ag ag ag
Diuretic: (loop)	 No I Yes → If Yes, s No I Yes → If Yes: DIULOOP <zyesno></zyesno> No I Yes → If Yes: 	Bumetanide BUMETA <zyes> I Ethacrynic acid ETHACR <zyes> I Furosemide FUROSE <zyes> I Torsemide TORSE <zyes> I Other (specify): OTHDILSP <v:60> OTHDIL <zyes></zyes></v:60></zyes></zyes></zyes></zyes>	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m TORSEDS <f:9:3> m OTHDILDS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D
Diuretic: (loop)	 No I Yes → If Yes, s No I Yes → If Yes: DIULOOP <zyesno></zyesno> No I Yes → If Yes: 	Bumetanide BUMETA <zyes> Ethacrynic acid ETHACR <zyes> Furosemide FUROSE <zyes> Torsemide TORSE <zyes> Other (specify): OTHDILSP <v:60> OTHDIL <zyes> Amiloride AMILO <zyes> Spironolactone SPIRO <zyes> Triamterene TRIAM <zyes></zyes></zyes></zyes></zyes></v:60></zyes></zyes></zyes></zyes>	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m TORSEDS <f:9:3> m OTHDILDS <f:9:3> m Total daily dose: AMILODS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D
Diuretic: (loop)	 No	Bumetanide BUMETA <zyes> Ethacrynic acid ETHACR <zyes> Furosemide FUROSE <zyes> Torsemide TORSE <zyes> Other (specify): OTHDILSP <v:60> OTHDIL <zyes> Amiloride AMILO <zyes> Spironolactone SPIRO <zyes> Triamterene TRIAM <zyes> Other (specify): OTHDIPSP <v:60></v:60></zyes></zyes></zyes></zyes></v:60></zyes></zyes></zyes></zyes>	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m OTHDILDS <f:9:3> m Total daily dose: AMILODS <f:9:3> m SPIRODS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D S Other CESFO> DIUR 1 (TYPE 3) ag ag ag ag ag ag ag ag
Diuretic: (loop)	 No	Bumetanide BUMETA <zyes> Ethacrynic acid ETHACR <zyes> Furosemide FUROSE <zyes> Torsemide TORSE <zyes> Other (specify): OTHDILSP <v:60> OTHDIL <zyes> Amiloride AMILO <zyes> Spironolactone SPIRO <zyes> Triamterene TRIAM <zyes></zyes></zyes></zyes></zyes></v:60></zyes></zyes></zyes></zyes>	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m TORSEDS <f:9:3> m OTHDILDS <f:9:3> m Total daily dose: AMILODS <f:9:3> m SPIRODS <f:9:3> m OTHDIPDS <f:9:3> m OTHDIPDS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D S Other CESFO> DIUR1 (TYPE 3) ag ag ag ag ag ag ag ag ag a
Diuretic: (loop) Diuretic: (potassium spari	 No	Bumetanide BUMETA <zyes> Ethacrynic acid ETHACR <zyes> Furosemide FUROSE <zyes> Torsemide TORSE <zyes> Other (specify): OTHDILSP < V:60> OTHDIL <zyes> Amiloride AMILO <zyes> Spironolactone SPIRO <zyes> Triamterene TRIAM <zyes> Other (specify): OTHDIPSP < V:60> OTHDIP <zyes> OTHDIP</zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes>	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m TORSEDS <f:9:3> m OTHDILDS <f:9:3> m Total daily dose: AMILODS <f:9:3> m SPIRODS <f:9:3> m OTHDIPDS <f:9:3> m OTHDIPDS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D S Other CESFO> DIUR1 (TYPE 3) ang ang ang ang ang ang ang ang ang an
Diuretic: (loop) Diuretic: (potassium spari	 No	Bumetanide BUMETA <zyes> Ethacrynic acid ETHACR <zyes> Furosemide FUROSE <zyes> Torsemide TORSE <zyes> Other (specify): OTHDILSP < V:60> OTHDIL <zyes> Amiloride AMILO <zyes> Spironolactone SPIRO <zyes> Triamterene TRIAM <zyes> Other (specify): OTHDIPSP < V:60> OTHDIP <zyes> OTHOROGOUND OTHDIPSP < V:60></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes>	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m TORSEDS <f:9:3> m OTHDILDS <f:9:3> m Total daily dose: AMILODS <f:9:3> m SPIRODS <f:9:3> m OTHDIPDS <f:9:3> m OTHDIPDS <f:9:3> m OTHDIPDS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D
Diuretic: (loop) Diuretic: (potassium spari	 No	Bumetanide BUMETA <zyes> Ethacrynic acid ETHACR <zyes> Furosemide FUROSE <zyes> Torsemide TORSE <zyes> Other (specify): OTHDILSP < V:60> OTHDIL <zyes> Amiloride AMILO <zyes> Spironolactone SPIRO <zyes> Triamterene TRIAM <zyes> Other (specify): OTHDIPSP < V:60> OTHDIP <zyes> OTHORONO OTHORONO <zyes> OTHORONO OTHORONO OTHORONO OTHORОNO OTHORONO OTHORONO OTHORОNO OTH</zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes>	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m TOTAL daily dose: OTHDILDS <f:9:3> m Total daily dose: AMILODS <f:9:3> m TRIAMDS <f:9:3> m OTHDIPDS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D 93 Other SESFQ> DIURI (TYPE 3) ng
Diuretic: (loop) Diuretic: (potassium spari	 No	Bumetanide BUMETA < ZYES> Ethacrynic acid ETHACR < ZYES> Furosemide FUROSE < ZYES> Torsemide TORSE < ZYES> Other (specify): OTHDILSP < V:60> OTHDIL < ZYES> Amiloride AMILO < ZYES> Spironolactone SPIRO < ZYES> Triamterene TRIAM < ZYES> Other (specify): OTHDIPSP < V:60> OTHDIP < ZYES> Other (specify): OTHDIPSP < V:60> OTHDIP < ZYES> Mydrochlorothiazide (diuril) CHLORO < ZYES> Hydrochlorothiazide (HCTZ) HCTZ < ZYES Metolazone (zaroxolyn) METOLA < ZYES	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m TOTAL daily dose: OTHDILDS <f:9:3> m Total daily dose: AMILODS <f:9:3> m TRIAMDS <f:9:3> m OTHDIPDS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D S Other CESFO> DIUR1 (TYPE 3) Ing Ing Ing Ing Ing Ing Ing In
Diuretic: (loop) Diuretic: (potassium spari	 No	Bumetanide BUMETA <zyes> Ethacrynic acid ETHACR <zyes> Furosemide FUROSE <zyes> Torsemide TORSE <zyes> Other (specify): OTHDILSP < V:60> OTHDIL <zyes> Amiloride AMILO <zyes> Spironolactone SPIRO <zyes> Triamterene TRIAM <zyes> Other (specify): OTHDIPSP < V:60> OTHDIP <zyes> OTHORONO OTHORONO <zyes> OTHORONO OTHORONO OTHORONO OTHORОNO OTHORONO OTHORONO OTHORОNO OTH</zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes></zyes>	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m TOTAL daily dose: OTHDILDS <f:9:3> m Total daily dose: AMILODS <f:9:3> m TRIAMDS <f:9:3> m OTHDIPDS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D S Other CESFO> DIUR1 (TYPE 3) Ing Ing Ing Ing Ing Ing Ing In
Diuretic: (loop) Diuretic: (potassium spari	 No	Bumetanide BUMETA < ZYES> Ethacrynic acid ETHACR < ZYES> Furosemide FUROSE < ZYES> Torsemide TORSE < ZYES> Other (specify): OTHDILSP < V:60> OTHDIL < ZYES> Amiloride AMILO < ZYES> Spironolactone SPIRO < ZYES> Triamterene TRIAM < ZYES> Other (specify): OTHDIPSP < V:60> OTHDIP < ZYES> Other (specify): OTHDIPSP < V:60> OTHDIP < ZYES> Mydrochlorothiazide (diuril) CHLORO < ZYES> Hydrochlorothiazide (HCTZ) HCTZ < ZYES Metolazone (zaroxolyn) METOLA < ZYES	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m TOTAL daily dose: OTHDILDS <f:9:3> m Total daily dose: AMILODS <f:9:3> m TRIAMDS <f:9:3> m OTHDIPDS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D S Other CESFQ> DIUR1 (TYPE 3) ag
Diuretic: (loop) Diuretic: (potassium spari	 No	Bumetanide BUMETA < ZYES> Ethacrynic acid ETHACR < ZYES> Furosemide FUROSE < ZYES> Torsemide TORSE < ZYES> Other (specify): OTHDILSP < V:60> OTHDIL < ZYES> Amiloride AMILO < ZYES> Spironolactone SPIRO < ZYES> Triamterene TRIAM < ZYES> Other (specify): OTHDIPSP < V:60> OTHDIP < ZYES> Other (specify): OTHDIPSP < V:60> OTHDIP < ZYES> Mydrochlorothiazide (diuril) CHLORO < ZYES> Hydrochlorothiazide (HCTZ) HCTZ < ZYES Metolazone (zaroxolyn) METOLA < ZYES	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m OTHDILDS <f:9:3> m OTHDILDS <f:9:3> m Total daily dose: AMILODS <f:9:3> m OTHDIPDS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D S Other CESFQ> DIUR1 (TYPE 3) ag ag ag ag ag ag ag ag ag a
Diuretic: (loop) Diuretic: (potassium spari	 No	Bumetanide BUMETA < ZYES> Ethacrynic acid ETHACR < ZYES> Furosemide FUROSE < ZYES> Torsemide TORSE < ZYES> Other (specify): OTHDILSP < V:60> OTHDIL < ZYES> Amiloride AMILO < ZYES> Spironolactone SPIRO < ZYES> Triamterene TRIAM < ZYES> Other (specify): OTHDIPSP < V:60> OTHDIP < ZYES> Other (specify): OTHDIPSP < V:60> OTHDIP < ZYES> Metolazone (zaroxolyn) METOLA < ZYES Other (specify): OTHDITSP < V:60> OTHDIT < ZYES> Other (specify): OTHDITSP < V:60> OTHDIT < ZYES> Other (specify): OTHDITSP < V:60> OTHDIT < ZYES>	Total daily dose: BUMETADS <f:9:3> m ETHACRDS <f:9:3> m FUROSEDS <f:9:3> m TORSEDS <f:9:3> m OTHDILDS <f:9:3> m Total daily dose: AMILODS <f:9:3> m OTHDIPDS <f:9:3> m OTHDIPDS <f:9:3> m Total daily dose: AMILODS <f:9:3> m TOTAL daily dose: CHLORODS <f:9:3> m TOTAL daily dose: CHLORODS <f:9:3> m TOTAL daily dose: CHLORODS <f:9:3> m TOTAL daily dose: TOTAL daily dose: AMILODIDS <f:9:3> m Total daily dose: AMILODIDS <f:9:3> m</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>	D S Other CESFQ> DIUR1 (TYPE 3) ag ag ag ag ag ag ag ag ag a

05/28/2004



Patient Number:		Patient Initials:
	site # nation! #	

Current Me	edications (co	ont.) (Ir	rclude all medic	ations patient was takin	
Beta blocker:	No		Bisoprolol BISC Carvedilol CA Metoprolol M Propranolol P	RVE <zeys> METO <zyes></zyes></zeys>	BBANTIAR (TYPE 3) ATENODS <f:9:3> mg BISODS <f:9:3> mg CARVEDS <f:9:3> mg METODS <f:9:3> mg PROPDS <f:9:3> mg OTHBBDS <f:9:3>mg</f:9:3></f:9:3></f:9:3></f:9:3></f:9:3></f:9:3>
Antiarrhythmics:	0 No 1 Yes -		I Amiodarone A I Dofetilide DC I Sotalol SOT I Other (specify): OTHAA < ZY	OFET <zyes></zyes>	Total daily dose: AMIODDS <f:9:3>mg DOFETDS <f:9:3>mg SOTADS <f:9:3> mg OTHAADS <f:9:3>mg</f:9:3></f:9:3></f:9:3></f:9:3>
Nitrates: Hydralazine:	0 No 1 Yes - NITRA <zyesn< th=""><th>IO></th><th>Isosorbide mor Topical nitrogly</th><th>trateDINIT <zyes> nonitrate MONONI <zyes> vcerin TOPNIT <zyes></zyes></zyes></zyes></th><th>Total daily dose: DINITDS <f:9:3>mg MONONIDS <f:9:3>mg TOPNITDS <f:9:3>mg HYDRADS <f:9:3>mg</f:9:3></f:9:3></f:9:3></f:9:3></th></zyesn<>	IO>	Isosorbide mor Topical nitrogly	trateDINIT <zyes> nonitrate MONONI <zyes> vcerin TOPNIT <zyes></zyes></zyes></zyes>	Total daily dose: DINITDS <f:9:3>mg MONONIDS <f:9:3>mg TOPNITDS <f:9:3>mg HYDRADS <f:9:3>mg</f:9:3></f:9:3></f:9:3></f:9:3>
Potassium:	HYDRA <zye -="" 1="" <zye<="" no="" o="" potas="" th="" yes=""><th>SNO> → If Yes, to SNO></th><th>otal daily dose:</th><th></th><th>POTASDS <f:9:3meq< th=""></f:9:3meq<></th></zye>	SNO> → If Yes, to SNO>	otal daily dose:		POTASDS <f:9:3meq< th=""></f:9:3meq<>
Other lipid lower	ED <esmed> ing agents:</esmed>	□ No	RSP <zyesno> Yes Yes</zyesno>	12-Antidepressants: 13-Benzodiazepines:	□ No □ Yes □ No □ Yes
Magnesium: Estrogen replacer Testosterone replacer	ment therapy: acement therapy:	□ No □ No	☐ Yes ☐ Yes ☐ Yes	14-Allopurinol: 15-Colchicine: 16-Enoxaparin:	No
Insulin: Oral diabetic age		□ No	Yes Yes	17=Warfarin: 18=Vitamin E:	No
Aspirin (daily): Other antiplatelet NSAIDs: Thyroid replacem		NoNoNoNoNo	☐ Yes☐ Yes☐ Yes☐ Yes	19_CoEnzyme Q10: 20=Other antioxidants: 21=Multi-vitamin:	 No ☐ Yes No ☐ Yes No ☐ Yes
				ecify study drug: OTHINVSE	
INFUNM <esinf></esinf>	INFRSP <zyesno i<="" no="" o="" th="" yes="" →="" ☐=""><th>)></th><th>Current infusion NFUDS <f:9:3> m</f:9:3></th><th>rate:</th><th>INFUS (TYPE 4) PS 2> # days/month</th></zyesno>)>	Current infusion NFUDS <f:9:3> m</f:9:3>	rate:	INFUS (TYPE 4) PS 2> # days/month
2= Dobutamine: 3= Dopamine:	 No		m		_ # days/month _ # days/month
= Milrinone:	No Yes → I		m		

5= Nitroglycerin

6= Nitroprusside

7= Natracor



atient Number:	site # notion! #	Patient Initials:
----------------	------------------	-------------------

	on Summary (Medi	Start dose:	Highest dose:	Total # Days:
IVINFMED <esiv></esiv>				(record whole number)
Intravenous Infusions:	IVINFRSP <zyesno></zyesno>	IVINFSDS <f:9:3></f:9:3>	IVINFHDS <f:9:3></f:9:3>	IVINFDAY <i:4></i:4>
1= Amrinone	\bigcirc No \bigcirc Yes \rightarrow If Yes:	mcg/kg/min	mcg/kg/min	
2= Dobutamine	\square No \square Yes \rightarrow If Yes:	mcg/kg/min	mcg/kg/min	
3= Dopamine	\square No \square Yes \rightarrow If Yes:	mcg/kg/min	mcg/kg/min	
4= Milrinone	\square No \square Yes \rightarrow If Yes:	mcg/kg/min	mcg/kg/min	
5= Nitroglycerin	No Yes → If Yes:	mcg/min	mcg/min	
6= Nitroprusside	□ No □ Yes → If Yes:	mcg/min	mcg/min	
7= Natracor		Highest total	Highest single	Total # Days:
MEDNAME <esmdnm></esmdnm>		daily dose:	daily dose:	(record whole number)
ACE inhibitors:	MEDNMRSP <zyesno></zyesno>	MEDTOTAL	MEDSINGL	
1= Benazepril	No 1 Yes → If Yes:	<f:9:3> mg</f:9:3>	MEDSINGL <f<u>:9:3> mg</f<u>	MEDNUM <i:4></i:4>
2= Captopril	□ No □ Yes → If Yes:	mg	mg	
3= Enalapril	□ No □ Yes → If Yes:	mg	mg	
4= Fosinopril	□ No □ Yes → If Yes:	mg	mg	
5= Lisinopril	□ No □ Yes → If Yes:	mg	mg	
6= Quinapril	□ No □ Yes → If Yes:	mg	mg	
7= Ramipril	□ No □ Yes → If Yes:	mg	mg	
8= Trandolapril	☐ No ☐ Yes → If Yes:	mg	mg	
9= Other	□ No □ Yes → If Yes:	mg	mg	
Angiotensin II antagonist:				
10=Candesartan	No Yes → If Yes:	mg	mg	
11=Losartan	\square No \square Yes \rightarrow If Yes:	mg	mg	
12=Valsartan	\square No \square Yes \rightarrow If Yes:	mg	mg	
13=Other	\square No \square Yes \rightarrow If Yes:	mg	mg	
Hydralazine:	\square No \square Yes \rightarrow If Yes:	mg	mg	
Isosorbide dinitrate:	No Yes → If Yes:	mg	mg	<u> </u>
Isosorbide mononitrate:	No Yes → If Yes:	mg	mg	<u> </u>
Topical nitroglycerin:	No Yes → If Yes:	mg	mg	
			Highest total	Total # Days:
			daily dose:	(record whole number)
MEDNM <esname></esname>	MEDMAMDE (7)	KEGNO.	PO IV	PO IV
Diuretic (loop):	MEDNAMRE <zy< td=""><td></td><td>MEDTOTPO MEDTOTI</td><td>MEDDAYFO _1.4</td></zy<>		MEDTOTPO MEDTOTI	MEDDAYFO _1.4
1= Bumetanide	O No I Yes → If		1.9.32 mg	<i:4>— (1.4></i:4>
2= Ethacrynic acid	□ No □ Yes → If		mg mg	
3= Furosemide	□ No □ Yes → If		mg mg	1 1
4= Torsemide	□ No □ Yes → If		mg mg	1 1
5= Other	☐ No ☐ Yes → If	Yes:	mg mg	
Diuretic (potassium sparing):	□ No □ Yes → If	. v		
6= Amiloride			mg	
7= Spironolactone 8= Triamterene	□ No □ Yes → If		mg	
9= Other	 No		mg	
Diuretic (thiazide):	∐ No ∐ Yes → If	162	mg mg	
10=Chlorothiazide (diuril)	□ No □ Yes → If	Voc.	ma ma	
			mg mg	
11-Hudrochlorothioside (U/	"T7\ No Voo → 1	+ Vor-		
11=Hydrochlorothiazide (HC 12=Metolazone (zaroxolyn)	CTZ)		mg mg	



Patient Number:		nationt #	Patient Initials:
-----------------	--	-----------	-------------------

Visual Analo	og Scale Scores (Complete the Visual Analog Scale Worksheet)	
Examination date:		VISUAL (TYPE 3)
Examination date.	day / month / year	
Worst symptom: _	WRSTSYM <u><i:3></i:3></u> → Corresponding to (Check only one): WRSTSYMP <eswrst> 1 Abdominal discomfort Breathing Breathing 3 Body swelling 4 Fatigue</eswrst>	
	DREATHING DRITHINGINA <ztes></ztes>	
Breathing:	CLODAL OR I Not applicable if breathing was selected as worst symptom	
Global:	GLOBAL <Ŀ3>	
Time Trade-	Off Scores	
Examination date:	,TIMEDT <dațe></dațe>	TIMETRAD (TYPE 3)
examination date:	day / TIMEDT < DATE >	
Score:	MESCRN < F.9.3 ONEDAY < ZYES > I or 1 day Indifferent = 1 INDIFF < ZY	F\$\
	TIMESCR <i:2></i:2>	LOZ
	alk Exercise Test	
WALKTST <zyest< th=""><th>tempt the 6-minute walk test? NO→ If No, specify primary reason: WALKRENO <eswlk> The patient was too critically ill to be taken out of bed and exercised. Patient cannot walk for technical reasons (e.g., a patient who is an amputee). Not done due to oversight.</eswlk></th><th>WALK (TYPE 3)</th></zyest<>	tempt the 6-minute walk test? NO→ If No, specify primary reason: WALKRENO <eswlk> The patient was too critically ill to be taken out of bed and exercised. Patient cannot walk for technical reasons (e.g., a patient who is an amputee). Not done due to oversight.</eswlk>	WALK (TYPE 3)
1	Yes → If Yes, complete below. Examination date: WALKDT < DATE> month /	
	00:00-23:59	
	End time of walk: WALKEDTM COATETIME>	
	WALKDIS WALKUNIT <eswkut> Total distance walked: <f:9:3></f:9:3></eswkut>	
	Did the patient experience any of the following symptoms (check all that apply):	
	Angina Angina <zyes></zyes>	
	Light headedness LGTHEAD <zyes></zyes>	
	Syncope SYNCOPE <zyes></zyes>	
	BORGSCOR Sorg Dyspnea score: <f:9:3> (Transcribe score from worksheet.)</f:9:3>	



Patient Number: _____ Patient Initials: _____

Echocardiogram D	ata
	ECHODT <date></date>
Examination date and time:	day month year ECHOTM < DATETIME>
al I	ECOSYSBP ECODIABP
Blood pressure (closest to start of	ECHO): <1:3> / diastolic diastolic
 Send ECHO tape to Brighar 	m Core Lab
Cardiopulmonary	Exercise (CPX)
	CPX (TYPE 3)
Did the patient attempt cardio	opulmonary exercise testing?
No → If	No, specify primary reason:
1	CPXRE <escpx> The patient was too critically ill to be taken out of bed and exercised.</escpx>
CPX <zyesno></zyesno>	The patient was unable to walk > 50 meters on the 6 minute walk.
3	Patient cannot walk for technical reasons (e.g., a patient who is an amputee).
	Not done due to oversight.
	Yes, complete below. CPXDT <date></date>
Ex	camination date:/
Tv	Pe of exercise (patient should perform same type of exercise throughout study): Bicycle
• •	2 Treadmill
Po	eak cardiovascular responses:
10	VO ₂ (ml/kg/min):
	VCO ₂ (ml/kg/min): VCO ₂ <f:9:3></f:9:3>
	VE max (L/min): VEMAX <f:9:3></f:9:3>
	VE/VCO ₂ (25 watts or end of first workload on treadmill) VEVCO ₂ <f:9:3></f:9:3>
	VO ₂ @ R = 1.0: VO2R <f:9:3></f:9:3>
	Heart rate (bpm): HRTRATE <1:3>
	Systolic BP (max): SYSBP <1:3>
	Diastolic BP (max): DIABP < 1:3>
	Duration of exercise (min): DUREX <f:9:3> DUREXS <f:9:3></f:9:3></f:9:3>
	Respiratory exchange ratio: REXCHNG <f:9:3></f:9:3>
	DUREXDM <f:9:3> := DUREX+(DUREXS/60) CPXTERM <esterm></esterm></f:9:3>
Re	eason for termination of testing (check primary reason):
	Patient completed testing
	2 Symptom limited (e.g., dyspnea, fatigue)
	3 Angina
	4 Serious arrhythmia
	5 Blood pressure changes
	6 No longer able to walk (e.g., leg cramps) Other
	The American



Patient Number: ____ Patient Initials: _____

Laboratory (Prior to rando	omization)			
Date of collection: LABDT		LABDAY <esini< th=""><th>HS></th><th>LAB (TYPE 4) PS</th></esini<>	HS>	LAB (TYPE 4) PS
Val			Value	
	BVAL LABUNIT <eslunt> 9:3></eslunt>	10 = AST/SGOT		IU/ _L or ^U / _L or ^{mIU} / _{mL}
2 = Platelets		11 = Total protein		□ a/ ^Γ □ a/ ^q Γ
3 = Hematocrit (Hct)	6 l/l 7%	12 = Albumin		□ 9/L □ 9/qr
4 = WBC	10 ^{9/} L OR 10 ^{3/} mm ³	13 = Total bilirubin		□ mg/dL □ μmol/L
5 = Sodium	8 mmol/L OR mEq/L	14 = Direct bilirubin		□ mg/dL □ μmol/L
6 = Potassium	mmol/L OR ^{mEq} /L	CKND <zyes> ☐ Not Done</zyes>		ENZYMES (TYPE 3)
7 = BUN	^{9 mg} /dL	CKMBULN CK-MB (ULN <f:9:3>) CKMBND <zyes> □ Not Done</zyes></f:9:3>	<f:9:3></f:9:3>	12 mcg/ _L or ^{µg} / _L or ^{ng} / _{mL} □ IU/ _L or ^U / _L or ^{mIU} / _{mL} □ %
8 = Creatinine	mg/dL	TROPTYP <estro> Troponin □ I □ T TROPULN (ULN ≤F:9:3>) □ Not Done TROPND<</estro>	<f:9:3></f:9:3>	L TROPPN <zposn: 19="" <sub="">mL or</zposn:>
9 = ALT/SGPT	10 IU/L OR U/L OR ^{mIU} /mL			



STUDYBOOK=ESCAPE FORM=INDEX HOSPT

Index Hospitalization

Patient Number: _____ - ____ Patient Initials: _____ _ Annotated the same as Page 11 site # _____ potient #

Laboratory			
Day 3 Value LABDAY <esinhs></esinhs>	Also Optimal Day Value (TYPE 4) DISDAY ZYES> Discharge Day record on page 29	Day 5 Value	☐ Also Optimal Day Value LABQUES ☐ Discharge Day record on page 29
Date of collection:	y / _{month} / _{year}	Date of collection:	y / _{month} / _{year}
WBC	\[\Bigcap \frac{10^{9/}}{\text{L OR } \frac{10^{3/}}{\text{mm}^3}} \]	WBC	\(\square\) \(\lambda \) \(\lambda
Sodium	mmol/L OR mEq/L	Sodium	mmol/L OR mEq/L
Potassium	mmol/L OR mEq/L	Potassium	mmol/L OR mEq/L
BUN	^{mg} / _{dL}	BUN	^{mg} / _{dL}
Creatinine	^{mg} /dL	Creatinine	^{mg} /dL
Day 7 Value	☐ Also Optimal Day Value LABQUES (TYPE 4) ☐ Discharge Day record on page 29	Optimal Day Value	RECELS <zyes> Recorded elsewhere (TYPE 4) Discharge Day record on page 29</zyes>
Date of collection:	y / month / year	Date of collection:	y / _{month} / _{year}
WBC		WBC	${\Box_{\text{mm}^3}}$
Sodium	mmol/L OR mEq/L	Sodium	mmol/L OR mEq/L
Potassium	mmol/L OR mEq/L	Potassium	mmol/L OR mEq/L
BUN	^{mg} / _d L	BUN	^{mg} / _d L
Creatinine	^{mg} /dL	Creatinine	^{mg} /dL

Annotated the same as Page 8

Index Hospitalization

Patient Number:	 Patient Initials:

Inpatient Medicat	Inpatient Medication Summary (Medications taken after randomization.)							
		Start dose:	Highest	dose:		Days:		
Intravenous Infusions:					,	,		
Amrinone	□ No □ Yes → If Yes:	mcg/kg/min	mo	g/kg/min				
Dobutamine	□ No □ Yes → If Yes:	mcg/kg/min		:g/kg/min	_			
Dopamine	□ No □ Yes → If Yes:	mcg/kg/min		:g/kg/min	_			
Milrinone	□ No □ Yes → If Yes:	mcg/kg/min		:g/kg/min	_			
Nitroglycerin	No Yes → If Yes:	mcg/min		g/min	_			
Nitroprusside	No Yes → If Yes:	mcg/min		g/min	_			
Niiroprosside	□ NO □ Tes → IT Tes.	-			_			
		Highest total daily dose:	Highest daily d		Total # (record who			
ACE inhibitors:	ŀ	,	<u> </u>					
Benazepril	\square No \square Yes \rightarrow If Yes:	mg	mg	, l				
Captopril	\square No \square Yes \rightarrow If Yes:	mg	mg	´				
Enalapril	\square No \square Yes \rightarrow If Yes:	mg	mg	, l				
Fosinopril	☐ No ☐ Yes → If Yes:	mg	mg					
Lisinopril	□ No □ Yes → If Yes:	mg	mg	·				
Quinapril	□ No □ Yes → If Yes:	mg	mg	· I				
Ramipril	□ No □ Yes → If Yes:	mg	mg	´				
Trandolapril	□ No □ Yes → If Yes:	mg	mg	´ l				
Other	□ No □ Yes → If Yes:	mg	mg	[']				
Angiotensin II antagonist:		—— ····ə		'				
Candesartan	No Yes → If Yes:	mg	mg	, [
Losartan	□ No □ Yes → If Yes:	mg	mg					
Valsartan	□ No □ Yes → If Yes:	mg	mg	[*]				
Other	No Yes → If Yes:	mg	mg	´ l				
Hydralazine:	□ No □ Yes → If Yes:	mg	mg	´				
Isosorbide dinitrate:	No Yes → If Yes	mg	mg	´				
Isosorbide mononitrate:	□ No □ Yes → If Yes:	mg	,	[*]		_		
Topical nitroglycerin:	□ No □ Yes → If Yes:		mg					
topical nifroglycerin:	☐ No ☐ fes → If fes:	mg	mg					
			Highest	_		Days:		
			daily o	iose:	PO (record wh	ole number) IV		
Diuretic (loop):				14	FO	14		
Bumetanide	□ No □ Yes → If Yes:		mg	mg				
Ethacrynic acid	No Yes → If Yes:		mg	mg				
Furosemide	□ No □ Yes → If Yes:		mg	mg				
Torsemide	No Yes → If Yes:		mg	mg				
Other	No Yes → If Yes:		mg	mg				
Diuretic (potassium sparing):								
Amiloride	No Yes → If Yes:		mg					
Spironolactone	☐ No ☐ Yes → If Yes:		mg					
Triamterene	☐ No ☐ Yes → If Yes:		mg					
Other	☐ No ☐ Yes → If Yes:		mg	mg				
Diuretic (thiazide):								
Chlorothiazide (diuril)	☐ No ☐ Yes → If Yes:		mg	mg				
Hydrochlorothiazide (HC			mg					
Metolazone (zaroxolyn)			mg					
Other	□ No □ Yes → If Yes:		mg	mg				

INPTMED1 (TYPE 4) PS

INPTMED2 (TYPE 4) PS

INPTMED3 (TYPE 4) PS



Index Hospitalization

Patient Number: Patient Initials: patient # **PAC Details** PACDTLS (TYPE 1) Did the patient receive a PAC at any time during the index hospitalization? No → If No, check primary reason: Randomized to CLIN 2 Randomized to PAC but catheter not placed due to (check only one): Abnormal anatomy PACRECV Other technical difficulties <ZYESNO> Change in patient condition 4 Physician preference 5 Withdrawal of consent

6 Death → Complete page 70, Event Notification Form AND Death Form (insert page) Other clinical event Yes → If Yes, check all that apply: Randomized to PAC (initial placement) → Was the PAC removed before the optimization of therapy (initial randomized insertion only)? PACREMVD <ZYESNO> 1 Yes → If Yes, check primary reason: PAC associated complications 2 Technical problems (e.g., balloon rupture, clot in catheter) 3 Change in patient condition ■ Death → Complete page 70, Event Notification Form AND Death Form (insert page) 98 Other (specify): OTHRESP < V:100> PACCROSS <ZYES>

☐ Crossover from CLIN to PAC (initial placement) → Complete Physician Estimate of Hemodynamic Status— Crossover Form (insert page) PACADD <ZYES>

■ Additional PAC placement → Complete the Additional PAC Insertion Form (insert page) for each PAC placement



Index Hospitalization

Patient Initials:

patient # This is not entered **PAC Insertion Details** Not applicable PACINSTM <DATETIME> PACINSRT (TYPE 3) PAC insertion date and time: Type of catheter (see codes in instructions): Reason for PAC:
PACRAND <ZYES>
I Initial PAC due to randomization Check up to 3 reasons: RENINSU <ZYES> CORONARY <ZYES

1 Acute coronary syndrome 1 Progressive oliguric renal insufficiency Assess transplant eligibility
DIAGNOS <ZYES>
Diagnostic uncertainty regarding hemodynamic profile
INABLTY ZYES>
Inability to wear in ofcosts
INOTROP <ZYES> Refractory symptomatic hypotension HYPSYSBP → Blood pressure: <I:3> __/_ <I:3> Need for increasing dose of inctropes WRSEDEMA <ZYES> Worsening pulmonary edema
OTHREAS < ZYES>
Other (specify): Need for mechanical ventilation Name of attending physician who performed or supervised PAC insertion: ___ Complications of PAC (Check Yes or No to each complication) Date of occurrence: (TYPE 4) P PCOMRSP <ZYESNO> PACCOMP < ESCCOM> 1=PAC associated bleeding requiring surgical intervention: 0 No 1 Yes → 2=PAC associated bleeding requiring transfusion: O No 1 Yes → 3=PAC associated pulmonary emboli: 0 No 1 Yes → 4=PAC associated cannulation of carotid artery: 0 No 1 Yes → 5=PAC associated VT > 30 seconds or VF: 0 No 1 Yes → 6=PAC associated thrombosis of a blood vessel: O No 1 Yes → 7=PAC associated complete heart block requiring pacemaker: 0 No 1 Yes → 1 Yes → 8-PAC associated perforation or rupture of pulmonary artery: 0 No 9=PAC associated pneumothorax: 0 No 1 Yes → 10=PAC knotting: O No ☐ Yes → 11=PAC associated valvular trauma: 0 No 1 Yes → O No 1 Yes → PAC associated infection: ELWBC <ZYES> Positive urine culture Need for IV antibiotics → If Yes, check all that apply: Elevated WBC PACCOMP2 TEMP38 ZYES>
Need for pressors due to sepsis I Infiltrate on chest x-ray ENDOCARD <ZYÉS> Positive catheter fip culture Positive blood cultures CPRREO <ZYESNO> PAC associated event requiring CPR: No 1 Yes → If Yes, complete Event Notification Form → If Yes, date of occurrence: EVNTONGO <ZYES> → If Yes, date of resolution: No 1 Yes → If Yes, complete Event Notification Form PAC associated pulmonary infarction/hemorrhage: INFDT <DATE> → If Yes, date of occurrence: INFONGO <ZYES> → If Yes, date of resolution: OR 1 Ongoing

Patient Number:



Additional PAC Insertion Form

Patie	ent Number:	site #	patient #	Patient Initials:
PAC Investigat Details to the control of	,		p-110.11 1	
PAC Insertion Details (Index hospitalization	on)			
PAC insertion date and time:/ _{month} /	year	_	00:00-23:5	PACINSRT (TYPE 3)
Type of catheter (see codes in instructions):				
Reason for PAC:				
☐ Initial PAC due to randomization OR				
Check up to 3 reasons:				
Acute coronary syndrome	Progress	sive oligu	ric renal insuf	ficiency
 ☐ Assess transplant eligibility ☐ Diagnostic uncertainty regarding hemodynamic profile 	Refracto	ry sympt	omatic hypote	
☐ Inability to wean inotropes	☐ Sepsis		→ в	lood pressure: /
Need for increasing dose of inotropes		ing pulm	onary edema	
Need for mechanical ventilation	Other (s	pecify):		
Name of physician who performed or supervised PA	C insertion: _			
Complications of PAC (Index hospitalization	on only)			
Check Yes or No to each complication.	7,			Date PACCOMP1 (TYPE 4) PS
PAC associated bleeding requiring surgical interventi	ion:	□No	☐ Yes →	/ /
PAC associated bleeding requiring transfusion:		□No	☐ Yes →	-day / month / year —
PAC associated pulmonary emboli:		□ No	Yes →	
PAC associated cannulation of carotid artery:		_ □ No	Yes →	
PAC associated VT > 30 seconds or VF:		□No	☐ Yes →	
PAC associated thrombosis of a blood vessel:		□No	☐ Yes →	
PAC associated complete heart block requiring pace	maker:	□ No	☐ Yes →	
PAC associated perforation or rupture of pulmonary		□No	☐ Yes →	/
PAC associated pneumothorax:	,	□No	☐ Yes →	/
PAC knotting:		□No	☐ Yes →	-day month year -
PAC associated valvular trauma:		□No	☐ Yes →	
PAC associated infection:		_ ∏ No	Yes →	day month year
→ If Yes, check all that apply: ☐ Elevated WBC			V antibiotics	day month year Positive urine culture
				sepsis Infiltrate on chest x-ray
Positive blood cult	tures Po	ositive ca	theter tip cultu	re Endocarditis
PAC associated event requiring CPR:		□No	☐ Yes → If Y	es, complete Event Notification Form
→ If Yes, date of occurre	ence: /		/	-
→ If Yes, date of resolut	,		,	
PAC associated pulmonary infarction/hemorrhage:	day			Yes, complete Event Notification Form
→ If Yes, date of occurre	ence: /			
→ If Yes, date of resolut				



Index Hospitalization

		Patient	Numbe		Patient Initials:
	Complications During Hospitaliz	ation			
	COMP <escom></escom>	COMPR No	RSP <zy Yes</zy 	NNA>	If Yes, date of first occurrence:
1=	ICD firing: Ventricular tachycardia/fibrillation	0	1	2	COMPDT <date>/</date>
2=	Inappropriate firing	0	1	2	day month year
3=	Cardiogenic shock (SBP < 60 mmHg requiring vasopressors)	0	1		day month year day month year
4=	Ischemia/Angina	0	1		
5=	Myocardial infarction	0			
6=	New atrial fibrillation/flutter	0	1		day / month /year → Complete MI Form
7=	·				day /- month year
	Pulmonary embolism	0	1		day/month/year
8=	Stroke	0	1		day / month year
9=	TIA	0	1		doy /- month /- year
	Cardiac arrest:	0	1		, ,
	0= Bradycardic arrest 1= Ventricular fibrillation	0	1		
į		_			
Ì	2= Ventricular tachycardia > 30 seconds	0	1		day/
	3= EMD/PEA 4= Undetermined cause	0	1		doy/month/year
	5= Other	0	1		doy/month/year
	Infection:	U	1		doy/month/year
	6= Sepsis	0	1		dev_ /month_ /vegr
1	7= Other infection requiring antibiotics	0	1		
	Procedures During Hospitalizat	ion			,
	Procedures During Hospitalizati	PROCRSI	P < 7YES	SNO>	PROC (TYPE 4) PS
1-	PROC <esproc> ICD implantation</esproc>	0	Yes	31102	If Yes, date of first occurrence: PROC (TYPE 4) PS PROCDT < DATE> day
2	CABG	0	1		day /month _ /year
3=	Left heart catheterization	0	1		, ,
4=	Cardiopulmonary resuscitation	0			doy /- month year
5=	Cardioversion	0	1		day /- month year
6=	Intra-aortic balloon pump	0	1		
7=	Left ventricular assist device	0	1		doy_ / month /year
8=	Mechanical ventilation	0	1		
9=	PTCI	0			day / month / year —
10=	Permanent pacemaker	0	1		day / month year
11=	Temporary pacemaker	0	1		day /- month /- year
12=	Other cardiac procedure/operation	0	1		/



Index Hospitalization

Patient Number: _____ - ____ Patient Initials: ___ ___

Daily Summary of Volume Status and PAC Insertion Site Status							
Date:	Net Fluid Status:	Insertion Site Status:					
VOLDT <date></date>	VOLSIGN < ESSIGN >	VOLUME (TYPE 2) Yes NA SITESTAT <zynna> 1 2 SITEST <zyesno> Exudate: 0 1</zyesno></zynna>					
/	+ cc	No Yes NA Erythema:					
/	+ cc	No Yes NA Erythema:					
day / month year —	+ cc	No Yes NA Erythema:					
/	+ cc	No Yes NA Erythema:					
day month year	+ cc	No Yes NA Erythema:					
/	+ cc	No Yes NA Erythema:					
/	+ cc	No Yes NA Erythema:					



3 Day Physician Assessment

	Patient N	umber: patient #	Patient Initials:
Heart Failure Clinical Assessr	nent—Syn	ptoms	
Does the patient have any of the following?	No Yes	1	SYMPTOMS (TYPE 3) No Yes
Fatigue: At rest		Dyspnea: At rest Walking in room Walking < 1 block	
Orthopnea (check only one): Needs only 1 p Occasional ort Needs 2 pillow Needs 3 pillow Needs 4 pillow	hopnea with 1 pil vs most of the time vs most of the time		
Gastrointestinal distress (check only one): None NYHA classification (check only one): I II	e 🗌 Occasion		
Heart Failure Clinical Assessr			
Heart rate (supine): bpm			bpm
Blood pressure manual cuff (supine):			·
Blood pressure manual cuff (standing after 3 minute	s):systolic	/ _{diastolic} mmHg	
Weight: Bb kg	,		
Respiratory rate: breaths/minute			
Temperature: C			
Jugular venous pulsation (cm above the right atrium	n):	8-12 12-16 >	16 Cannot measure
Rales: ☐ None ☐ < 1/3 ☐ 1/3-2/3	□ > 2/3		
Auscultation: S3: No Yes Estimated P2-PAS: < 40	40-50] 51-60	
Hepatomegaly (check only one): Absent	2-4 finger bree	adths 🗌 > 4 finger bread	hs
Hepatojugular reflux: No Yes			
Ascites (check only one): None Trace	Moderate	Massive	
Peripheral edema (check only one): 0 0 1	+ 2+	3+ 4+	
Extremities (check only one): Cool Lukev	varm War	m	
Valsalva maneuver (check only one): Normal	Absent ov	ershoot 🗌 Square-wave	Uncertain OR Not applicable
Clinical profile (check only one): Dry/warm	☐ Wet/warm	☐ Dry/cold ☐ Wet/co	old
Signature (Physician who perfo	rmed asses	sment)	
Investigator's signature:	E AS PAGE 3	Date performed:	SIGNATUR (TYPE 4)



5 Day Physician Assessment

Page 22

Patient Number: Patient Initials: patient # **Heart Failure Clinical Assessment—Symptoms** SYMPTOMS (TYPE 3) Does the patient have any of the following? No Yes Yes Dyspnea: Fatigue: П At rest At rest Walking in room Any activity Walking < 1 block Routine daily activity Orthopnea (check only one): □ Needs only 1 pillow Occasional orthopnea with 1 pillow Needs 2 pillows most of the time ☐ Needs 3 pillows most of the time ■ Needs 4 pillows most of the time (sitting up) Gastrointestinal distress (check only one): None Occasional Ocnstant NYHA classification (check only one): Heart Failure Clinical Assessment—Physical Exam Heart rate (supine): ___ __ bpm Heart rate (standing after 3 minutes): ___ _ bpm Blood pressure manual cuff (supine): _____systolic / _____diastolic mmHg Blood pressure manual cuff (standing after 3 minutes): _____ vistalia / ____ diastolic mmHg Respiratory rate: ___ breaths/minute Temperature: ___ __ _ _ _ _ _ _ _ C _ _ F Jugular venous pulsation (cm above the right atrium): < 8 8 8-12 12-16 >16 Cannot measure Rales: ☐ None ☐ < 1/3 ☐ 1/3-2/3 ☐ > 2/3 Auscultation: S3: No Yes Estimated P2-PAS: < 40 40-50 51-60 > 60 Hepatomegaly (check only one): ☐ Absent ☐ 2-4 finger breadths ☐ > 4 finger breadths Hepatojugular reflux: No Yes Ascites (check only one): None Trace Moderate Massive Peripheral edema (check only one): 0 0 1+ 2+ 3+ 4+ Extremities (check only one): Cool Lukewarm Warm Valsalva maneuver (check only one): Normal Absent overshoot Square-wave Uncertain OR Not applicable Clinical profile (check only one): Dry/warm Wet/warm Dry/cold Wet/cold Signature (Physician who performed assessment) SIGNATUR (TYPE 4) SAME AS PAGE 3 Investigator's signature: ____



Patient Number:

7 Day Physician Assessment

Patient Initials:

patient # **Heart Failure Clinical Assessment—Symptoms** Does the patient have any of the following? SYMPTOMS (TYPE 3) Yes Yes Dyspnea: Fatigue: At rest At rest Walking in room Any activity Walking < 1 block Routine daily activity ☐ Needs only 1 pillow Orthopnea (check only one): Occasional orthopnea with 1 pillow Needs 2 pillows most of the time □ Needs 3 pillows most of the time ☐ Needs 4 pillows most of the time (sitting up) Gastrointestinal distress (check only one): None Occasional Occasional NYHA classification (check only one): Heart Failure Clinical Assessment—Physical Exam Heart rate (supine): ___ _ bpm Heart rate (standing after 3 minutes): ___ __ bpm Blood pressure manual cuff (supine): _____systolic | mmHg Blood pressure manual cuff (standing after 3 minutes): _____ / ____ diastolic mmHg Weight: ___ __ . __ 🗆 lb 🗆 kg Respiratory rate: ___ breaths/minute Temperature: ___ _ _ _ _ _ _ _ _ _ C _ _ F Jugular venous pulsation (cm above the right atrium): < 8 8-12 12-16 >16 Cannot measure Rales: ☐ None ☐ < 1/3 ☐ 1/3-2/3 ☐ > 2/3 Auscultation: S3: No Yes Hepatomegaly (check only one): ☐ Absent ☐ 2-4 finger breadths ☐ > 4 finger breadths Hepatojugular reflux: No Yes Ascites (check only one): None Trace Moderate Massive Peripheral edema (check only one): 0 0 1+ 2+ 3+ 4+ Extremities (check only one): Cool Lukewarm Warm Valsalva maneuver (check only one): Normal Absent overshoot Square-wave Uncertain OR Not applicable Clinical profile (check only one): Dry/warm Wet/warm Dry/cold Wet/cold Signature (Physician who performed assessment) SAME AS PAGE 3 SIGNATUR (TYPE 4) Investigator's signature:



SAME AS PAGE 2 Optimal-Day Physician Assessment

Patient Number: _____site # Patient Initials: **Heart Failure Clinical Assessment—Symptoms** Does the patient have any of the following? SYMPTOMS (TYPE 3) Yes Yes Dyspnea: Fatigue: At rest At rest Walking in room Any activity Walking < 1 block Routine daily activity Orthopnea (check only one): ■ Needs only 1 pillow Occasional orthopnea with 1 pillow Needs 2 pillows most of the time ☐ Needs 3 pillows most of the time Needs 4 pillows most of the time (sitting up) Gastrointestinal distress (check only one): None Occasional Ocnstant NYHA classification (check only one): Heart Failure Clinical Assessment—Physical Exam Heart rate (supine): ____ bpm Heart rate (standing after 3 minutes): ____ bpm Blood pressure manual cuff (supine): ________ / ______ diastolic mmHg Blood pressure manual cuff (standing after 3 minutes): _____ / ____ diastolic mmHg Weight: ___ _ _ _ _ _ _ | Respiratory rate: ___ breaths/minute Temperature: ___ __ _ _ _ _ _ _ _ C _ _ F Jugular venous pulsation (cm above the right atrium): < 8 8 8-12 12-16 >16 Cannot measure Auscultation: S3: No Yes Estimated P2-PAS: < 40 40-50 51-60 > 60 Hepatomegaly (check only one): ☐ Absent ☐ 2-4 finger breadths ☐ > 4 finger breadths Hepatojugular reflux: No Yes Ascites (check only one): None Trace Moderate Massive Peripheral edema (check only one): 0 0 1+ 2+ 3+ 4+ Extremities (check only one): Cool Lukewarm Warm Valsalva maneuver (check only one): Normal Absent overshoot Square-wave Uncertain OR Not applicable Clinical profile (check only one): Dry/warm Wet/warm Dry/cold Wet/cold Signature (Physician who performed assessment) SAME AS PAGE 3 SIGNATUR (TYPE 4) Investigator's signature:



STUDYBOOK=ESCAPE FORM=DISCHARGE

SAME AS PAGE 2

Discharge Physician Assessment

		Patient N	lumber: patient #	Patient Initials:
Heart Failure Clinical Asses	smo.	at_Sym	,,,,	
		II—37II	ipionis	SYMPTOMS (TYPE 3)
Does the patient have any of the following?	No	Yes	I	No Yes
Fatigue:	М	163	Dyspnea:	NO 163
At rest			At rest	
Any activity			Walking in room	
Routine daily activity			Walking < 1 block	
Orthopnea (check only one): Needs only Coccasional Needs 2 pil Needs 3 pil Needs 4 pil Gastrointestinal distress (check only one):	orthopnows mo lows mo lows mo lows mo one	ea with 1 pil st of the time st of the time st of the time	e e (sitting up) aal Constant	
Heart Failure Clinical Asses	smei	nt—Phy	sical Exam	
Heart rate (supine): bpm	Hea	rt rate (star	nding after 3 minutes):	bpm
Blood pressure manual cuff (supine):	tolic /	diastolic	mmHg	
Blood pressure manual cuff (standing after 3 min	utes):	systolic	/ diastolic mmHg	
Weight: 🗆 lb 🗆 kg				
Respiratory rate: breaths/minute				
Temperature: □ C □	F			
Jugular venous pulsation (cm above the right at	rium):	< 8	8-12	Cannot measure
Rales: ☐ None ☐ < 1/3 ☐ 1/3-2/3	3 🗌	> 2/3		
Auscultation: S3: No Yes Estimated P2-PAS: < 40	_ 4	0-50	51-60	
Hepatomegaly (check only one): Absent	_ 2-4	4 finger bre	adths	
Hepatojugular reflux: No Yes				
Ascites (check only one): None Trace	_ N	Noderate	Massive	
Peripheral edema (check only one): 0] 1+	_ 2+ [3+ 4+	
Extremities (check only one): Cool Lul	kewarm	War	m	
Valsalva maneuver (check only one): Norm	nal [Absent ov	vershoot Square-wave	Uncertain OR Not applicable
Clinical profile (check only one): Dry/warm		Net/warm	□ Dry/cold □ Wet/cold	



Investigator's signature:

Discharge Physician Assessment

Patient Number: _____ - ____ patient # Patient Initials: ___ ___ Heart Failure Clinical Assessment—Estimate of Hemodynamic Status Right atrial pressure (mmHg) (check only one): < 8 8-12 13-16 >16 THIS NOT ENTERED Certainty of assessment (check only one): Certainty of assessment (check only one): Cardiac index (L/min \bullet m²) (check only one): \square < 1.8 \square 1.8-2.2 \square 2.3-2.5 \square > 2.5 Certainty of assessment (check only one): not very sure -Physician Estimate of Likelihood of Death over next 6 months PHYDTH <ESEST> PHYSEST (TYPE 3) 0-25% Check only one: 26-50% 3 51-75% 4 76-100% Physician Estimate of Readmission over next 6 months PHYREADM <ESEST> Check only one: 26-50% 3 51-75% 4 76-100% Signature (Physician who performed assessment) SAME AS PAGE 3 SIGNATUR (TYPE 4)



Discharge

Patient Number: _____ - ____patient #

Patient	Initials:			
---------	-----------	--	--	--

Visual Analog Scale Scores (Complete the Visual Analog Scale Worksheet).	
	VISUAL (TYPE 3)
Examination date:/	
Worst symptom: → Corresponding to (Check only one):	
Breathing: OR	
Time Trade-Off Scores	
Examination date: /	THIS NOT ENTERED
6 Minute Walk Exercise Test	
Did the patient attempt the 6-minute walk test? □ No → If No, specify primary reason:	WALK (TYPE 3)
☐ The patient was too critically ill to be taken out of bed and exer	
Patient cannot walk for technical reasons (e.g., a patient who is	an amputee).
☐ Not done due to oversight.	
Yes → If Yes, complete below. Examination date:/	
Start time of walk:;	
End time of walk::::	
Total distance walked:	
Did the patient experience any of the following symptoms (check all Angina Light headedness Syncope Borg Dyspnea score: (Transcribe score from worksheet.)	



Discharge

Patient Number: Patient Initials: _____ patient # Echocardiogram Data ECHO (TYPE 3) Examination date and time: _____/ ___ _{month} ____/ ___ _{year} Blood pressure (closest to start of ECHO): _____ /____ diostolic diostolic Send ECHO tape to Brigham Core Lab Cardiopulmonary Exercise (CPX) CPX (TYPE 3) Did the patient attempt cardiopulmonary exercise testing? No → If No, specify primary reason: The patient was too critically ill to be taken out of bed and exercised. ☐ The patient was unable to walk > 50 meters on the 6 minute walk. Patient cannot walk for technical reasons (e.g., a patient who is an amputee). Not done due to oversight. Yes → If Yes, complete below. ☐ Bicycle Type of exercise (patient should perform same type of exercise throughout study): Treadmill Peak cardiovascular responses: VO₂ (ml/kg/min): VCO2 (ml/kg/min): VE max (L/min): VE/VCO₂ (25 watts or end of first workload on treadmill) VO2 @ R = 1.0: Heart rate (bpm): Systolic BP (max): Diastolic BP (max): Duration of exercise (min): Respiratory exchange ratio: Reason for termination of testing (check primary reason): Patient completed testing Symptom limited (e.g., dyspnea, fatigue) ☐ Angina Serious arrhythmia Blood pressure changes No longer able to walk (e.g., leg cramps)

Other



Discharge

Patient Number:		
	site #	patient #

Patient	Initials:		
r ancin	minuta.	 	

Laboratory			Optimal Day Value
Date of collection:	/ _{month} / _{year}		LAB (TYPE 4) PS
	Value	Value	
Hemoglobin (Hgb)	□ 9/ _L □ mmol/ _L □ 9/ _{dL}	AST/SGOT	^{IU} / _L or ^U / _L or ^{mIU} / _{mL}
Platelets	\Bigcup 10 ^{9/} L OR 10 ^{3/} mm ³ \Bigcup /mm ³	Total protein	— □9/ _{dL}
Hematocrit (Hct)	□ ι _{/ι} □%	Albumin	_ □ 9/ _L □ 9/ _L
WBC		Total bilirubin	
Sodium	mmol/L OR mEq/L	Direct bilirubin	□ mg/dL □ μmol/L
Potassium	mmol/L OR mEq/L	CK (ULN =)	IU/ _L or U/ _L or ^{mIU} / _{mL}
		☐ Not Done	
BUN	^{mg} /dL	CK-MB (ULN =)	
		☐ Not Done	
Creatinine	^{mg} / _{dL}	Troponin □ I □ T) □ Not Done	_ng/ _{mL} or ☐ Positive ☐ Negative
ALT/SGPT	IU/LORU/LOR MIU/mL		



Discharge

		Patient Number:patient #	Patient Initials:
Discharge	Medications		
ACE inhibitor:	□ No → If No, specify red	Angioedema, anaphylaxis, neutropenia Cough Hyperkalemia Renal artery stenosis Renal dysfunction Symptomatic hypotension	ACE1 (TYPE 3)
	☐ Yes → If Yes:	Other adverse events such as taste disturbance, Benazepril Captopril Enalapril Fosinopril Lisinopril Quinapril Ramipril Trandolapril Other (specify):	ACE2 (TYPE 3) Total daily dose: mg
Angiotensin II ar			Total daily dose:
Digoxin:	No Yes → If Yes:		mg mg mg mg mg
			QD QOD Other
Diuretic: (loop)	□ No □ Yes → If Yes:	☐ Bumetanide ☐ Ethacrynic acid ☐ Furosemide ☐ Torsemide ☐ Other (specify):	Total daily dose: mg mg mg mg mg mg mg mg
Diuretic: (potassium sparir	□ No □ Yes → If Yes:		Total daily dose: mg mg mg mg mg
Diuretic: (thiazide)	□ No □ Yes → If Yes:	□ Chlorothiazide (diuril) □ Hydrochlorothiazide (HCTZ) □ Metolazone (zaroxolyn) □ Other (specify):	Total daily dose: mg mg mg mg mg
Calcium channel			Total daily dose:
	☐ No ☐ Yes → If Yes:	☐ Amlodipine ☐ Other (specify):	mg



Oral diabetic agents:

Other antiplatelet agents:

Thyroid replacement therapy:

Aspirin (daily):

NSAIDs:

Amrinone: Dobutamine:

Dopamine:

SAME AS PAGE 7

Discharge

			Patient Number:	site # patient #	Patient Initials:
Discharge	Medicat	ions (cont.)) .		
Beta blocker:		Yes → If Yes:	☐ Atenolol ☐ Bisoprolol ☐ Carvedilol ☐ Metoprolol ☐ Propranolol		Total daily dose: BBANTIAR (TYFE 3) mg mg mg mg mg mg
			Other (specify):		mg
Antiarrhythmics:	□ No □	Yes → If Yes:	Amiodarone Dofetilide Sotalol Other (specify):		Total daily dose: mg mg mg mg
Nitrates:	□No □	Yes → If Yes:	☐ Isosorbide dinitrate ☐ Isosorbide mononitrate ☐ Topical nitroglycerin	mg	Total daily dose: mg mg
Hydralazine:	□ No □	Yes → If Yes, to	otal daily dose:		mg
Potassium:	□ No □	Yes → If Yes, to	otal daily dose:		mEq
Statins:	to	□ No	Yes	Antidepressants: Benzodiazepines:	□ No □ Yes MEDS (TYPE 4) PS □ No □ Yes
Other lipid lowerin Magnesium:	g agenis:	□ No	res □ Yes	Allopurinol:	□ No □ Yes
Estrogen replacem	ent therapy:	□ No [Yes	Colchicine:	□ No □ Yes
Testosterone replac	cement thera	ру : П No [Yes	Enoxaparin:	□ No □ Yes
Insulin:		□ No [Yes	Warfarin:	☐ No ☐ Yes

Current/Intermittent Infusions

No Yes → If Yes:

No Yes → If Yes:

No Yes → If Yes:

☐ No

☐ No

☐ No

☐ No

☐ No

Yes Yes

Yes

Yes

Yes

Yes

 mcg/kg/min	 # days/month	INFUS (TYPE 4) PS
 mcg/kg/min	 # days/month	

Vitamin E:

CoEnzyme Q10:

Multi-vitamin:

Other antioxidants:

☐ No

☐ No

☐ No

☐ No

days/month

Yes

Yes

Yes

Yes

_ mcg/kg/min



Discharge

Patient Number: _____ Patient Initials: ___ ___

Nurse/Study Coordinate	r Estimate	of Likeliho	od of Dec	ath over next 6 months
Check only one: 1 0-25%	RSDTH <esest: 2 26-50%</esest: 	3 51-75%	4 76-100%	NURSEEST (TYPE 3)
Nurse/Study Coordinate			sion ove	r next 6 months
Check only one: 1 0-25%	NRSREADM <1 2 26-50%	ESEST> 3 51-75%	<u>4</u> 76-100%	Ó
ECG (Record results of ECG closest	to time of disch	narge.)		
Date and time:/ _{month} /	SAME AS	S PAGE 5 		ECG (TYPE 3)
Rate: bpm				
Rhythm (check only one): Sinus bradycardio Atrial fibrillation/	flutter 🗌 Paced r	hythm 🗌 Other	,	
Specific abnormalities (check all that apply):			ole	
Endpoint Summary: Inde	x Hospitali	zation		
Number of days since randomization the	patient was in:	ICU/CCU: IC Step down unit: Regular ward:	STPNUM <i:3> WRDNUM <</i:3>	
Since randomization has the patient died PTDIED ZYESN No → If No, transplant status	O check only one): T I Inelig Activ Listed Rece	e evaluation	Date:	NUMTIMES <1:2> CRDOPPRO <zyesno> RECDT <date> /</date></zyesno>
$\boxed{1} \ Yes \to If \ Yes, \ complete \ page$	70, Event Notifica	tion Form and the	e Death Form	insert page)
→ If Yes, DO NOT compl	ete remainder of t	this page.		
Discharge Summary				
Patient status: 1 Discharged home 2 DISCHDT <date <="" date:="" discharge="" th=""><th></th><th>ed living 3 Disc</th><th>harged to skille</th><th>d nursing facility DISCHARG (TYPE 1)</th></date>		ed living 3 Disc	harged to skille	d nursing facility DISCHARG (TYPE 1)
On discharge, was the patient relieved of RELIEV <zyesno> 0 No</zyesno>	f congestion? → If No, diuresis v		eck only one):	DIULMIT <esdiur> 1 Renal dysfunction 2 Hypotension 98 Other</esdiur>
Discharge Instructions for Sodium and Flo			< <u>F:9:3></u> mg/	
Was the patient given a diuretic plan for	PL.	No $\boxed{1}$ Yes \rightarrow If	FLDRES L/d <f:9:3> Yes, for every eck all that apply)</f:9:3>	2 lb weight gain patient:
				loop diuretics INCLOOP <zyes> zide/metolazone ADDTHMET <zyes></zyes></zyes>



STUDYBOOK=ESCAPE FORM=2-WEEK FOLLOW-UP

Patient Number:

patient #

2-Week Follow-Up

Patient Initials:

Contact Status Date of contact: CONTACT (TYPE 3) MODEC<ESCON> Mode of contact (check only one): 1 Clinic visit 2 Telephone call 3 Rehospitalization 4 Continuous hospitalization since randomization LSTCONDT <DATE> 98 Other (specify): OTHMDESP < V:100> Resuscitation Orders RESUSORD <ESRESU>
Attempt cardiopulmonary resuscitation Resuscitation orders (check only one): Attempt cardiopulmonary resuscitation but do not intubate 3 Do not attempt cardiopulmonary resuscitation Endpoint Summary (SKIP this box for patients with a continuous hospitalization since randomization.) Since the last visit was the patient admitted to the hospital or emergency department for more than 24 hours? SAME AS PAGE 32 ☐ Yes → If Yes, number of times: → If Yes, complete the Rehospitalization Form (insert page) for each hospital admission Since the last visit has the patient undergone a cardiovascular operation or procedure (e.g., CABG, PAC, mechanical ventilation)? □N₀ ☐ Yes → If Yes, complete the CV Procedures/Mechanical Ventilation Form (insert page) Since the last visit has the patient died? No → If No, transplant status (check only one): Ineligible Active evaluation \square Received transplant \rightarrow **Date:** $____{day}$ / $_____{month}$ / $_____{year}$ $__$ Accepted, but waiting to determine need after discharge Not evaluated ☐ Yes → If Yes, complete page 70, Event Notification Form and the Death Form (insert page)



2-Week Physician Assessment

	Patient N	lumber: patient #	Patient Initials:
Heart Failure Clinical Assessm	ient – Syr	mptoms	
Does the patient have any of the following?			SYMPTOMS (TYPE3)
No.	o Yes		No Yes
Fatigue:	·	Dyspnea:	
At rest Any activity		At rest Walking in room	
Routine daily activity		Walking < 1 block	
Orthopnea (check only one): Needs only 1 pil Occasional ortho Needs 2 pillows Needs 3 pillows Needs 4 pillows	opnea with 1 pil most of the time most of the time most of the time	e e s (sitting up)	
Gastrointestinal distress (check only one): ☐ None NYHA classification (check only one): ☐ I ☐ II			
Heart Failure Clinical Assessm			
Heart rate (supine): bpm	leart rate (star	nding after 3 minutes):	bpm PHYSEXAM (TYPE 3)
Blood pressure manual cuff (supine):	/ diastolic	mmHg	
Blood pressure manual cuff (standing after 3 minutes)	systolic	/ _{diastolic} mmHg	
Weight:			
Respiratory rate: breaths/minute			
Temperature: C			
Jugular venous pulsation (cm above the right atrium):	:	8-12	Cannot measure
Rales: ☐ None ☐ < 1/3 ☐ 1/3-2/3	> 2/3		
Auscultation: S3: ☐ No ☐ Yes Estimated P2-PAS: ☐ < 40 ☐	_ 40-50	51-60	
Hepatomegaly (check only one): Absent	2-4 finger bre	adths 🗌 > 4 finger breadths	s
Hepatojugular reflux: No Yes			
Ascites (check only one): None Trace	Moderate	Massive	
Peripheral edema (check only one): 0 0 1+	+	3+ 4+	
Extremities (check only one): Cool Lukewo	arm 🗌 Warr	m	
Valsalva maneuver (check only one): Normal	Absent ov	vershoot Square-wave	Uncertain OR Not applicable
Clinical profile (check only one): Dry/warm	Wet/warm	☐ Dry/cold ☐ Wet/cold	d
Signature (Physician who perform			
Investigator's signature:	ME AS PAGE 3	3 Date performed:/	SIGNATUR (TYPE 4)



2-Week Follow-Up

		Patient Number:	Patient Initials:
Current M	edications		
ACE inhibitor:	No → If No, specify	reason (check all that apply): Angioedema, anaphylaxis, neutropenia Cough Hyperkalemia Renal artery stenosis Renal dysfunction Symptomatic hypotension Other adverse events such as taste disturbance,	rash, and gastrointestinal upset ACE2 (TYPE 3) Total daily dose:
	☐ Yes → If Yes:	Benazepril Captopril Enalapril Fosinopril Lisinopril Quinapril Ramipril Trandolapril Other (specify):	
Angiotensin II an	tagonist: ☐ No ☐ Yes → If Yes:	□ Candesartan □ Losartan □ Valsartan □ Other (specify):	ANGIODIG (TYPE 3)
Digoxin:	□ No □ Yes → If Yes,	specify total dose and frequency:	mg QD
Diuretic: (loop)	□ No □ Yes → If Yes:	☐ Bumetanide ☐ Ethacrynic acid ☐ Furosemide ☐ Torsemide ☐ Other (specify):	Total daily dose: mg mg mg mg mg mg mg
Diuretic: (potassium sparir	□ No □ Yes → If Yes:	☐ Amiloride ☐ Spironolactone ☐ Triamterene ☐ Other (specify):	Total daily dose: mg mg mg mg
Diuretic: (thiazide)	□ No □ Yes → If Yes:	☐ Chlorothiazide (diuril) ☐ Hydrochlorothiazide (HCTZ) ☐ Metolazone (zaroxolyn) ☐ Other (specify):	DIURCCB (TYPE 3)
Calcium channel	blocker: ☐ No ☐ Yes → If Yes:	□ Amlodipine □ Other (specify):	Total daily dose: mg mg



2-Week Follow-Up

				Patient Nur		site # patient #	Patient Initials:
ı							
	Current Me	edications (co	nt.)				
Ì							Total daily dose:
	Beta blocker:	☐ No ☐ Yes →	If Yes:	Atenolol			mg
۱				Bisoprolol			mg
ı				Carvedilol Metoprolol			mg
ı				☐ Propranolol			mg mg
ı				_ '			mg
ŀ							Total daily dose:
١	Antiarrhythmics:	□ No □ Yes →	If Yes	Amiodarone			mg
ı	7			☐ Dofetilide			mg
ı				☐ Sotalol			mg
l				Other (specify):			mg
Ì							Total daily dose:
l	Nitrates:	☐ No ☐ Yes →	If Yes:	Isosorbide dinit	trate		mg
I				Isosorbide mon			mg
l				Topical nitrogly	cerin		mg
I	Hydralazine:	☐ No ☐ Yes →	If Yes, t	otal daily dose:			mg
l	Potassium:	☐ No ☐ Yes →	If Yes, t	otal daily dose:			mEq
I	Statins:		□No	Yes	Δ	antidepressants:	□ No □ YMEDS (TYPE 4) PS
I	Other lipid lower	ing agents:	☐ No	Yes	В	enzodiazepines:	☐ No ☐ Yes
I	Magnesium:		☐ No	Yes Yes	Δ	llopurinol:	☐ No ☐ Yes
I	Estrogen replace	ment therapy:	☐ No	Yes	C	Colchicine:	☐ No ☐ Yes
I	Testosterone repl	acement therapy:	☐ No	Yes Yes	E	noxaparin:	☐ No ☐ Yes
I	Insulin:		☐ No	Yes Yes	٧	Varfarin:	☐ No ☐ Yes
I	Oral diabetic age	ents:	☐ No	Yes	٧	'itamin E:	☐ No ☐ Yes
I	Aspirin (daily):		☐ No	Yes	C	oEnzyme Q10:	☐ No ☐ Yes
I	Other antiplatele	t agents:	☐ No	Yes	C	Other antioxidants:	☐ No ☐ Yes
I	NSAIDs:		☐ No	Yes	٨	Aulti-vitamin:	☐ No ☐ Yes
l	Thyroid replacem	nent therapy:	□No	Yes			
I	INFUDG <esinf></esinf>	INFDGRSP <z< th=""><th>YESNO></th><th>Current infusion I</th><th>rate:</th><th>Check box if in INFINT <zyes></zyes></th><th>termittent!NFUSIN (TYPE 4) PS</th></z<>	YESNO>	Current infusion I	rate:	Check box if in INFINT <zyes></zyes>	termittent!NFUSIN (TYPE 4) PS
ı	Amrinone:	0 No 1 Yes → If	Yes:	<f:9:3> m</f:9:3>	ıcg/kg/mi		<i:2> # days/month</i:2>
I	Dobutamine:	No	Yes:	m	ıcg/kg/mi	n 1 Intermittent	# days/month
I	Dopamine:	No	Yes:	m	ıcg/kg/mi	n	# days/month
ı	Milrinone:	0 No 1 Yes → If	Yes:	m	ıcg/kg/mi	n 1 Intermittent	# days/month
ı	Nitroglycerin:	No	Yes:	m	cg/min		
ł	Nitroprusside:	0 No 1 Yes → If	Yes:	m	icg/min		

7= Natracor



2-Week Follow-Up

LUVAL	SAME AS P Patient Numl	Patient Initials:	
Laboratory			
	y / year		LAB (TYPE 4) PS
	Value	Va	lue
Hemoglobin (Hgb)	□ 9/dr □ mmol/r □ 9/r	AST/SGOT	IU/L OR U/L OR ^{mIU} /mL
Platelets	\(\bigcap \frac{10^{9/}}{L} \text{ OR } \(\bigcap \frac{10^{3/}}{mm^3} \) \(\bigcap \cdot \limits \frac{10^{3/}}{mm^3} \)	Total protein	□ a/Γ □ a/qr
Hematocrit (Hct)	□ L _{/L} □%	Albumin	□ a/f □ a/qr
WBC	10 ⁹ / _L OR 10 ³ / _{mm} 3	Total bilirubin	□ mg/dL □ μmol/L
Sodium	mmol/L or mEq/L	Direct bilirubin	□ mg/dL □ μmol/L
Potassium	mmol/L OR mEq/L	CK (ULN =)	U/L OR U/L OR mIU/mL
		☐ Not Done	
BUN	mg/dL	CK-MB (ULN =)	☐ mcg/ _L or μg/ _L or ng/ _{mL} ☐ IU/ _L or U/ _L or mIU/ _{mL} ☐ %
		☐ Not Done	
Creatinine	mg/dL	Troponin □ I □ T) (ULN =) □ Not Done	ng/ _{mL} or \square Positive \square Negative
		□ Nor Done	

_____IU/LORU/LOR MIU/mL

ALT/SGPT



2-Week Follow-Up

Patient Initials: ___ ___

Patient Number: _____ - ____patient # **Follow-Up Summary** FOLLOW (TYPE 3) Follow-Up Instructions for Sodium and Fluid Restriction: Sodium restriction: F:9:3> mg/day **FLUID** Fluid restriction: <u><F:9:3></u> L/day WTPLAN <ZYESNO> (check all that apply) Increases loop diuretics INCDIU <ZYES> Adds thiazide/metolazone. ADDSTHI <ZYES> Visual Analog Scale Scores (Complete the Visual Analog Scale Worksheet insert pages) VISUAL (TYPE 3) Examination date: Abdominal discomfort Worst symptom: ___ _ → Corresponding to (check only one): Breathing ■ Body swelling Fatigue Breathing: ___ _ OR Not applicable if breathing was selected as worst symptom Global: Nurse/Study Coordinator Estimate of Likelihood of Death over next 6 months 0-25% Check only one: 26-50% THIS NOT ENTERED 51-75% 76-100% Nurse/Study Coordinator Estimate of Readmission over next 6 months 0-25% Check only one: 26-50% THIS NOT ENTERED 51-75% 76-100% Signature SIGNATUR (TYPE 4) The data recorded on CRF pages 1-38 have been reviewed by me or my delegate and are accurate and complete to the best of my knowledge SAME AS PAGE 3 _____ Date: ____ / ___ _{month} ___ / ___ _{year} ___ Investigator's signature: ___



STUDYBOOK=ESCAPE FORM=1-MONTH FOLLOW-UP

SAME AS PAGE 1

1-Month Follow-Up

Patient Number:		Patient Initials:
	site # patient #	

Minnesota Living with Heart Failure

Instructions: These questions concern how your heart failure (heart condition) has prevented you from living as you wanted during the last month. The items listed below describe different ways some people are affected. If you are sure an item does not apply to you or is not related to your heart failure then circle 0 (meaning "No") and go onto the next item. If an item does apply to you, then circle the number rating of how much it prevented you from living as you wanted. Remember to think about ONLY THE LAST MONTH.

LWHFQUES (TYPE 3)

Did your heart failure prevent you from living as you wanted during the LAST MONTH by:

	No	Very Little			->	Very Much
1. causing swelling in your ankles, legs, etc?	0	1	2	3	4	5
2. making your working around the house or yard difficult?	0	1	2	3	4	5
3. making your relating to or doing things with your friends difficult?	0	1	2	3	4	5
4. making you sit or lie down to rest during the day?	0	1	2	3	4	5
5. making you tired, fatigued, or low on energy?	0	1	2	3	4	5
6. making your working to earn a living difficult?	0	1	2	3	4	5
7. making your walking or climbing stairs difficult?	0	1	2	3	4	5
8. making you short of breath?	0	1	2	3	4	5
9. making your sleeping well at night difficult?	0	1	2	3	4	5
10. making you eat less of the foods you like?	0	1	2	3	4	5
11. making your going places away from home difficult?	0	1	2	3	4	5
12. making your sexual activities difficult?	0	1	2	3	4	5
13. making your recreational pastimes, sports, or hobbies difficult?	0	1	2	3	4	5
14. making it difficult for you to concentrate or remember things?	0	1	2	3	4	5
15. giving you side effects from medications?	0	1	2	3	4	5
16. making you worry?	0	1	2	3	4	5
17. making you feel depressed?	0	1	2	3	4	5
18. costing you money for medical care?	0	1	2	3	4	5
19. making you feel a loss of self-control in your life?	0	1	2	3	4	5
20. making you stay in a hospital?	0	1	2	3	4	5
21. making you feel you are a burden to your family or friends?	0	1	2	3	4	5



1-Month Follow-Up

Patient Initials: ___ ___

Contact Status SAME AS PAGE 33 CONTACT (TYPE 3) Mode of contact (check only one): Clinic visit Telephone call Rehospitalization Continuous hospitalization since randomization Other (specify): **Resuscitation Orders** Resuscitation orders (check only one): Attempt cardiopulmonary resuscitation Attempt cardiopulmonary resuscitation but do not intubate Do not attempt cardiopulmonary resuscitation Endpoint Summary (SKIP this box for patients with a continuous hospitalization since randomization.) SAME AS PAGE 32

Since the last visit was the patient admitted to the hospital or emergency department for more than 24 hours? **ENDPTSUM (TYPE 3)** Yes → If Yes, number of times: _____ → If Yes, complete the Rehospitalization Form (insert page) for each hospital admission Since the last visit has the patient undergone a cardiovascular operation or procedure (e.g., CABG, PAC, mechanical ventilation)? □No ☐ Yes → If Yes, complete the CV Procedures/Mechanical Ventilation Form (insert page) Since the last visit has the patient died? No→ If No, transplant status (check only one): Ineligible Active evaluation Listed ☐ Received transplant → Date: ____day / ____month / ____year ___ Accepted, but waiting to determine need after discharge ■ Not evaluated ☐ Yes → If Yes, complete page 70, Event Notification Form and the Death Form (insert page)

Patient Number:

patient #



1-Month Physician Assessment

SAME AS PAGE 2 Patient Number: _____ Patient Initials: _____

Heart Failure Clinical Assessment—Symptoms		
Does the patient have any of the following?	SYMPTOMS	(TYPE 3)
No Yes	No	Yes
Fatigue: At rest Dyspnea: At rest At rest	П	П
Any activity Walking in room		
Routine daily activity Walking < 1 block		
Orthopnea (check only one): Needs only 1 pillow Occasional orthopnea with 1 pillow Needs 2 pillows most of the time Needs 3 pillows most of the time Needs 4 pillows most of the time (sitting up)		
Gastrointestinal distress (check only one): ☐ None ☐ Occasional ☐ Constant NYHA classification (check only one): ☐ I ☐ II ☐ III ☐ IV		
Heart Failure Clinical Assessment—Physical Exam	PHYSEXAM	(TVDF 3)
Heart rate (supine): bpm Heart rate (standing after 3 minutes):	bpm	(111123)
Blood pressure manual cuff (supine):systolic /diastolic mmHg		
Blood pressure manual cuff (standing after 3 minutes):systolic mmHg		
Weight:		
Respiratory rate: breaths/minute		
Temperature:		
Jugular venous pulsation (cm above the right atrium):	Cannot measure	
Rales: ☐ None ☐ < 1/3 ☐ 1/3-2/3 ☐ > 2/3		
Auscultation: S3: ☐ No ☐ Yes Estimated P2-PAS: ☐ < 40 ☐ 40-50 ☐ 51-60 ☐ > 60		
Hepatomegaly (check only one): Absent 2-4 finger breadths > 4 finger breadths		
Hepatojugular reflux: No Yes		
Ascites (check only one): None Trace Moderate Massive		
Peripheral edema (check only one): 0 0 1+ 2+ 3+ 4+		
Extremities (check only one): Cool Lukewarm Warm		
Valsalva maneuver (check only one): Normal Absent overshoot Square-wave Un	certain OR Not c	ıpplicable
Clinical profile (check only one): Dry/warm Wet/warm Dry/cold Wet/cold		



Investigator's signature:

1-Month Physician Assessment

Patient Number: _____ - ____patient # Patient Initials: ___ ___ Heart Failure Clinical Assessment—Estimate of Hemodynamic Status THIS NOT ENTERED Pulmonary capillary wedge pressure (mmHg) (check only one): < 12 12-22 23-30 >30 Certainty of assessment (check only one): 1 2 3 4 5 Physician Estimate of Likelihood of Death over next 6 months PHYSEST (TYPE 3) SAME AS PAGE 26 0-25% Check only one: 26-50% 51-75% ☐ 76-100% Physician Estimate of Readmission over next 6 months Check only one: 0-25% 26-50% □ 51 – 75% 76-100% Signature (Physician who performed assessment) SAME AS PAGE 3 SIGNATUR (TYPE 4)



1-Month Follow-Up

		Patient Number:patient #	Patient Initials:
Current M	edications		
ACE inhibitor:	□ No → If No, specify red	ason (check all that apply): Angioedema, anaphylaxis, neutropenia Cough Hyperkalemia Renal artery stenosis Renal dysfunction Symptomatic hypotension Other adverse events such as taste disturbance	ACE1 (TYPE 3) e, rash, and gastrointestinal upset
	☐ Yes → If Yes:	Benazepril Captopril Enalapril Fosinopril Lisinopril Quinapril Ramipril Trandolapril Other (specify):	mg m
Angiotensin II an	tagonist: ☐ No ☐ Yes → If Yes:	Candesartan Losartan Valsartan Other (specify):	ANGIODIG (TYPE 3) Total daily dose: mg mg mg mg
Digoxin:	□ No □ Yes → If Yes,	specify total dose and frequency:	mg QD QOD Other
Diuretic: (loop)	□ No □ Yes → If Yes:	Bumetanide Ethacrynic acid Furosemide Torsemide Other (specify):	Total daily dose: mg mg mg mg mg mg mg
Diuretic: (potassium sparir	□ No □ Yes → If Yes:	Amiloride Spironolactone Triamterene Other (specify):	Total daily dose: mg mg mg mg
Diuretic: (thiazide)	□ No □ Yes → If Yes:	Chlorothiazide (diuril) Hydrochlorothiazide (HCTZ) Metolazone (zaroxolyn) Other (specify):	Total daily dose: mg mg mg mg mg
Calcium channel	blocker: ☐ No ☐ Yes → If Yes:	☐ Amlodipine	Total daily dose:



1-Month Follow-Up

			Patient Number:	site # patient #	Patient Initials:
Current M	edications (co	nt l			
Correm M	salcanons (co	,			DRANTIAD (TVDE 2)
Beta blocker:	□ No □ Yes →	If Yes:	Atenolol Bisoprolol Carvedilol Metoprolol Propranolol Other (specify):		Total daily BRANTIAR (TYPE 3)
Antiarrhythmics:	□ No □ Yes →	• If Yes:	Amiodarone Dofetilide Sotalol Other (specify):		Total daily dose: mg mg mg mg
Nitrates:	□ No □ Yes →	If Yes:	☐ Isosorbide dinitrate ☐ Isosorbide mononitrate ☐ Topical nitroglycerin		NIHYPOT (TYPE 3)
Hydralazine:	☐ No ☐ Yes →	If Yes, to	otal daily dose:		mg
Potassium:	☐ No ☐ Yes →	If Yes, to	otal daily dose:		mEq
Statins:		□No	Yes	Antidepressants:	□ No □ Yes (TYPE 4) PS
Other lipid lowe	ring agents:	□No	□ v	Benzodiazepines:	□ No □ Yes
Magnesium:			Yes	benzouldzepines:	140 163
		□No	Yes	Allopurinol:	□ No □ Yes
Estrogen replace	ement therapy:	□ No		•	
-	ement therapy: lacement therapy:	_	Yes	Allopurinol:	□ No □ Yes
-		□ No	Yes Yes	Allopurinol: Colchicine:	No Yes
Testosterone rep	lacement therapy:	□ No	Yes Yes Yes	Allopurinol: Colchicine: Enoxaparin:	No Yes No Yes No Yes
Testosterone rep	lacement therapy:	No No	Yes Yes Yes Yes	Allopurinol: Colchicine: Enoxaparin: Warfarin:	No Yes No Yes No Yes No Yes No Yes
Testosterone rep Insulin: Oral diabetic ag Aspirin (daily): Other antiplatele	lacement therapy:	No	Yes Yes Yes Yes Yes Yes	Allopurinol: Colchicine: Enoxaparin: Warfarin: Vitamin E: CoEnzyme Q10: Other antioxidants:	No Yes No Yes No Yes No Yes No Yes No Yes
Testosterone rep Insulin: Oral diabetic ag Aspirin (daily): Other antiplatele NSAIDs:	lacement therapy: ents: et agents:	X	 Yes 	Allopurinol: Colchicine: Enoxaparin: Warfarin: Vitamin E: CoEnzyme Q10:	No Yes No Yes No Yes No Yes No Yes No Yes
Testosterone rep Insulin: Oral diabetic ag Aspirin (daily): Other antiplatele	lacement therapy: ents: et agents:	No	 Yes 	Allopurinol: Colchicine: Enoxaparin: Warfarin: Vitamin E: CoEnzyme Q10: Other antioxidants: Multi-vitamin:	No Yes
Testosterone rep Insulin: Oral diabetic ag Aspirin (daily): Other antiplatele NSAIDs:	lacement therapy: ents: et agents:	X	 Yes 	Allopurinol: Colchicine: Enoxaparin: Warfarin: Vitamin E: CoEnzyme Q10: Other antioxidants: Multi-vitamin:	No Yes
Testosterone rep Insulin: Oral diabetic ag Aspirin (daily): Other antiplatele NSAIDs:	lacement therapy: ents: et agents:	No	 Yes 	Allopurinol: Colchicine: Enoxaparin: Warfarin: Vitamin E: CoEnzyme Q10: Other antioxidants: Multi-vitamin:	No Yes
Testosterone rep Insulin: Oral diabetic ag Aspirin (daily): Other antiplatele NSAIDs: Thyroid replacen	lacement therapy: ents: et agents: nent therapy:	No	Yes	Allopurinol: Colchicine: Enoxaparin: Warfarin: Vitamin E: CoEnzyme Q10: Other antioxidants: Multi-vitamin: Check box if	No
Testosterone rep Insulin: Oral diabetic ag Aspirin (daily): Other antiplatele NSAIDs: Thyroid replacen	lacement therapy: ents: et agents: nent therapy: □ No □ Yes → If	No	Yes	Allopurinol: Colchicine: Enoxaparin: Warfarin: Vitamin E: CoEnzyme Q10: Other antioxidants: Multi-vitamin: Check box if min	No Yes intermittent: # days/month
Testosterone rep Insulin: Oral diabetic ag Aspirin (daily): Other antiplatele NSAIDs: Thyroid replacen Amrinone: Dobutamine:	lacement therapy: ents: et agents: nent therapy: No Yes → If	No	Yes Yes Yes Yes Yes Yes Yes Yes Yes Current infusion rate:	Allopurinol: Colchicine: Enoxaparin: Warfarin: Vitamin E: CoEnzyme Q10: Other antioxidants: Multi-vitamin: Check box if min	No Yes Intermittent: INFUSIN (TYPE 4) PS → # days/month → # days/month
Testosterone rep Insulin: Oral diabetic ag Aspirin (daily): Other antiplatele NSAIDs: Thyroid replacen Amrinone: Dobutamine: Dopamine:	lacement therapy: ents: et agents: nent therapy: No Yes → If No Yes → If	No	Yes	Allopurinol: Colchicine: Enoxaparin: Warfarin: Vitamin E: CoEnzyme Q10: Other antioxidants: Multi-vitamin: Check box if min	No Yes Intermittent: # days/month → # days/month → # days/month → # days/month



1-Month Follow-Up

	Patient Numb	er: patient #	Patient Initials:
Laboratory			
	y /		LAB (TYPE 4) PS
	Value	V	alue
Hemoglobin (Hgb)	□ 9/dL □ mmol/L □ 9/L	AST/SGOT	IU/ _L or ^U / _L or ^{mIU} / _{mL}
Platelets	□ 10 ^{9/} L OR 10 ^{3/} mm ³ □ /mm ³	Total protein	□ 9/ [[]
Hematocrit (Hct)		Albumin	□ a\rac{\text{\Gamma}}{\text{qr}}
WBC	□ 10 ^{9/} L OR 10 ^{3/} mm ³	Total bilirubin	□ mg/dL □ μmol/L
Sodium	mmol/L OR mEq/L	Direct bilirubin	□ μmol/L
Potassium	mmol/L OR mEq/L	CK (ULN =)	IU/ _L OR V/ _L OR mIU/ _{mL}
BUN	^{mg} /dL	CK-MB (ULN =) □ Not Done	$ \Box \ ^{\text{mcg}}/_{\text{L}} \text{ or } ^{\text{Hg}}/_{\text{L}} \text{ or } ^{\text{ng}}/_{\text{mL}} $ $ \Box \ ^{\text{IU}}/_{\text{L}} \text{ or } ^{\text{U}}/_{\text{L}} \text{ or } ^{\text{mIU}}/_{\text{mL}} $ $ \Box \ ^{\%} $
Creatinine	^{mg} / _{dL}	Troponin □ I □ T	ng/ _{mL} or □ Positive □ Negative
ALT/SGPT	IU/L OR U/L OR MIU/mL		



1-Month Follow-Up

		Patient Number:	site # patient #	Patient Initials:
Follow-Up Su	mmary			
	for Sodium and Fluid Re	estriction: SAME AS P.	AGE 38	FOLLOW (TYPE 3)
Sodium restriction:				
Fluid restriction:	L/day			
Was the patient given o	a diuretic plan for weigl	nt gain? No Ye	s → If Yes, for every 2 lb (check all that apply)	weight gain patient:
			☐ Increases loop di	
			Adds thiazide/me	
Visual Analog			l Analog Scale Works	
Examination date:	/	nth year.	SAME AS PAGE 9	VISUAL (TYPE 3)
Worst symptom:			☐ Abdominal discomfo ☐ Breathing ☐ Body swelling ☐ Fatigue	ort
Breathing:	OR	plicable if breathing was s	selected as worst symptom	
Global:	<u> </u>			
Congestion S	core (See instruction	ons on facing page.)		
Congestion score:	CONGSCOR <i:1></i:1>			CONGEST (TYPE 1)
Time Trade-Of	f Scores			
Examination date: _	/	SAME AS F	PAGE 9	TIMETRAD (TYPE 3)
	months	_		
Nurse/Study	Coordinator Es	stimate of Like	lihood of Death	over next 6 months
Check only one:	□ 0-25% □ 26-50% □ 51-75% □ 76-100%	SAME AS F	PAGE 32	NURSEEST (TYPE 3)
Nurse/Study	Coordinator Es	stimate of Rea	dmission over n	ext 6 months
Check only one:	□ 0-25% □ 26-50% □ 51-75% □ 76-100%			
Signature				
	ges 39-46 have been reviewe	d by me or my delegate and a	are accurate and complete to the	SIGNATUR (TYPE 4) best of my knowledge.
Investigator's signature	:		Date:/	



STUDYBOOK=ESCAPE FORM=2-MONTH FOLLOW-UP

Patient Number:

2-Month Follow-Up

Patient Initials: ___ ___

patient # Contact Status CONTACT (TYPE 3) Date of contact: Mode of contact (check only one): Clinic visit Telephone call Rehospitalization Continuous hospitalization since randomization Other (specify): **Resuscitation Orders** Resuscitation orders (check only one): Attempt cardiopulmonary resuscitation Attempt cardiopulmonary resuscitation but do not intubate Do not attempt cardiopulmonary resuscitation Endpoint Summary (SKIP this box for patients with a continuous hospitalization since randomization.) Since the last visit was the patient admitted to the hospital or emergency department for more than 24 hours? ☐ No Yes → If Yes, number of times: _____ → If Yes, complete the Rehospitalization Form (insert page) for each hospital admission Since the last visit has the patient undergone a cardiovascular operation or procedure (e.g., CABG, PAC, mechanical ventilation)? □ No ☐ Yes → If Yes, complete the CV Procedures/Mechanical Ventilation Form (insert page) Since the last visit has the patient died? No → If No, transplant status (check only one): Ineligible Active evaluation Listed Accepted, but waiting to determine need after discharge Not evaluated ☐ Yes → If Yes, complete page 70, Event Notification Form and the Death Form (insert page)



2-Month Physician Assessment

Patient Number: Patient Initials: ___ ___ **Heart Failure Clinical Assessment – Symptoms** SYMPTOMS (TYPE 3) Does the patient have any of the following? Yes Yes Dyspnea: Fatigue: At rest At rest П Walking in room Any activity Walking < 1 block Routine daily activity Orthopnea (check only one): ■ Needs only 1 pillow Occasional orthopnea with 1 pillow ■ Needs 2 pillows most of the time ■ Needs 3 pillows most of the time ■ Needs 4 pillows most of the time (sitting up) Gastrointestinal distress (check only one): None Occasional Occasional NYHA classification (check only one): Heart Failure Clinical Assessment - Physical Exam PHYSEXAM (TYPE 3) Heart rate (standing after 3 minutes): _____ Heart rate (supine): ___ __ bpm Blood pressure manual cuff (supine): _____systolic | mmHg Blood pressure manual cuff (standing after 3 minutes): _____ visible | _____ / ____ diastolic | mmHg Weight: ___ _ _ . _ _ | D lb | kg Respiratory rate: ___ breaths/minute Jugular venous pulsation (cm above the right atrium): < 8 8 8-12 12-16 >16 Cannot measure Auscultation: S3: No Yes Estimated P2-PAS: < 40 40-50 51-60 > 60 **Hepatomegaly** (check only one): ☐ Absent ☐ 2-4 finger breadths ☐ > 4 finger breadths Hepatojugular reflux: No Yes Ascites (check only one): None Trace Moderate Massive Peripheral edema (check only one): 0 0 1+ 2+ 3+ 4+ Extremities (check only one): Cool Lukewarm Warm Valsalva maneuver (check only one): Normal Absent overshoot Square-wave Uncertain OR Not applicable Clinical profile (check only one): Dry/warm Wet/warm Dry/cold Wet/cold Signature (Physician who performed assessment) SIGNATUR (TYPE 4) SAME AS PAGE 3 Investigator's signature:



2-Month Follow-Up

		Patient Number:patient #	Patient Initials:
Current M	ledications		
ACE inhibitor:		reason (check all that apply): Angioedema, anaphylaxis, neutropenia Cough Hyperkalemia Renal artery stenosis Renal dysfunction Symptomatic hypotension	ACE1 (TYPE 3)
		Other adverse events such as taste disturbance	, rash, and gastrointestinal upset ACE2 (TYPE 3 Total daily dose:
	☐ Yes → If Yes:	Benazepril Captopril Enalapril Fosinopril Lisinopril Quinapril Ramipril Trandolapril Other (specify):	mg m
Angiotensin II an	tagonist:		ANGIODIG (TYPE 3
	□ No □ Yes → If Ye	es: Candesartan Losartan Valsartan Other (specify):	mg mg mg mg
Digoxin:	☐ No ☐ Yes → If Ye	es, specify total dose and frequency:	mg QD QOD Other
Diuretic: (loop)	□ No □ Yes → If Yes	s: Bumetanide Ethacrynic acid Furosemide Torsemide Other (specify):	Total daily dose: mg mg mg mg mg mg mg mg
Diuretic: (potassium spari	□ No □ Yes → If Ye:	s: Amiloride Spironolactone Triamterene Other (specify):	Total daily dose:
Diuretic: (thiazide)	□ No □ Yes → If Ye	s: Chlorothiazide (diuril) Hydrochlorothiazide (HCTZ) Metolazone (zaroxolyn) Other (specify):	DIURCCB (TYPE 3
Calcium channel	blocker:		Total daily dose:
	☐ No ☐ Yes → If Yes	S: Amlodipine	mg



2-Month Follow-Up

Patient Number: _____ Patient Initials: _____

Current Me	edications (cor	nt.)				
						Total daily RBANTIAR (TYPE 3)
Beta blocker:	☐ No ☐ Yes →	If Yes:	Atenolol			mg
			☐ Bisoprolol			mg
			Carvedilol			mg
			Metoprolol			mg
			Propranolol			mg
			Other (specify):	:		mg
						Total daily dose:
Antiarrhythmics:	□ No □ Yes →	If Yes:	Amiodarone			mg
			 Dofetilide 			mg
			Sotalol			mg
I			Other (specify)):		mg
						Total daily dose:
Nitrates:	☐ No ☐ Yes →	If Yes:	☐ Isosorbide dir	nitrate		mg
	_		Isosorbide mo	ononitrate		mg
			☐ Topical nitrog	glycerin		mg
Hydralazine:	□ No □ Yes →	If Yes, to	otal daily dose:			mg
Potassium:	☐ No ☐ Yes →	If Yes, to	otal daily dose:			mEq
Statins:		□No	Yes	Antide	epressants:	□ No □ YMEDS (TYPE 4) PS
Other lipid lower	ring agents:	□No	Yes		diazepines:	□ No □ Yes
Magnesium:	3.5	□No	Yes		rinol:	□ No □ Yes
Estrogen replace	ement therapy:	□No	Yes	Colchi		□ No □ Yes
-	lacement therapy:	□No	Yes	Enoxa	ıparin:	□ No □ Yes
Insulin:		☐ No	Yes	Warfa	ırin:	☐ No ☐ Yes
Oral diabetic ag	ents:	□No	Yes	Vitami	in E:	☐ No ☐ Yes
Aspirin (daily):		□No	Yes	CoEnz	yme Q10:	☐ No ☐ Yes
Other antiplatele	et agents:	□No	Yes	Other	antioxidants:	☐ No ☐ Yes
NSAIDs:		☐ No	Yes	Multi-v	vitamin:	☐ No ☐ Yes
Thyroid replacen	nent therapy:	□No	Yes			
	SAME AS PAG	E 36	Current infusion	n rate:	Check box if	intermittent! INFUSIN (TYPE 4) PS
Amrinone:	□ No □ Yes → If	Yes:		mcg/kg/min	☐ Intermittent	→ # days/month
Dobutamine:	\square No \square Yes \rightarrow If	Yes:		mcg/kg/min	☐ Intermittent	→ # days/month
Dopamine:	\square No \square Yes \rightarrow If	Yes:		mcg/kg/min	☐ Intermittent	→ # days/month
Milrinone:	\square No \square Yes \rightarrow If	Yes:		mcg/kg/min	Intermittent	→ # days/month
Nitroglycerin:	\square No \square Yes \rightarrow If	Yes:		mcg/min		
Nitroprusside:	\square No \square Yes \rightarrow If	Yes:		mcg/min		



2-Month Follow-Up

	Patient Number:	 patient #	Patient Initials:
aboratory			

Laboratory Date of collection:			LAB (TYPE 4) PS
Date of collection:	ry month year		
	Value	Value	
Hemoglobin (Hgb)	□ a\ ^q Γ □ wwol\ ^r □ a\ ^r	AST/SGOT	IU/LORU/LORMIU/mL
Platelets	□ 10 ^{9/} L OR 10 ^{3/} mm ³ □ /mm ³	Total protein	_ □9/L □9/dL
Hematocrit (Hct)	——— □ L/L □%	Albumin	— □ 9/dL □ 9/L
WBC	□ 10 ^{9/} L OR 10 ^{3/} mm ³ □ / _{mm³}	Total bilirubin	□ mg/ _{dL} □ μmol/ _L
Sodium	mmol/L OR mEq/L	Direct bilirubin	— □ πωο \Γ □ □ mg\qΓ
Potassium	mmol/L OR mEq/L	CK (ULN =)	IU/LORU/LOR ^{MIU} /mL
BUN	^{mg} / _{dL}	CK-MB (ULN =)	□ mcg/ _L or μg/ _L or ^{ng} / _{mL} □ ^{IU} / _L or ^U / _L or ^{mIU} / _{mL} □ %
Creatinine	^{mg} / _{dL}	Troponin □ I □ T) □ Not Done	_ng/ _{mL} or □ Positive □ Negative
ALT/SGPT	IU/ _L or ^U / _L or ^{mIU} / _m L		



2-Month Follow-Up

Patient Initials: ___ ___

Patient Number: _____ - ___patient # Follow-Up Summary Follow-Up Instructions for Sodium and Fluid Restriction: SAME AS PAGE 38 FOLLOW (TYPE 3) Sodium restriction: ____ mg/day Fluid restriction: _____ L/day Was the patient given a diuretic plan for weight gain? ☐ No ☐ Yes → If Yes, for every 2 lb weight gain patient: (check all that apply) Increases loop diuretics Adds thiazide/metolazone Visual Analog Scale Scores (Complete the Visual Analog Scale Worksheet insert pages) VISUAL (TYPE 3) Examination date: Worst symptom: ___ _ → Corresponding to (check only one): ☐ Abdominal discomfort Breathing ■ Body swelling Fatigue Breathing: ___ __ OR Not applicable if breathing was selected as worst symptom Global: Time Trade-Off Scores SAME AS PAGE 9 TIMETRAD (TYPE 3) Examination date: ___ months or 1 day Nurse/Study Coordinator Estimate of Likelihood of Death over next 6 months Check only one: 0-25% THIS NOT ENTERED 26-50% 51-75% 76-100% Nurse/Study Coordinator Estimate of Readmission over next 6 months 0-25% Check only one: 26-50% THIS NOT ENTERED **51-75%** 76-100% Signature SAME AS PAGE 3

The data recorded on CRF pages 47-52 have been reviewed by me or my delegate and are accurate and complete to the best of my knowledge.



STUDYBOOK=ESCAPE FORM=3-MONTH FOLLOW-UP

3-Month Follow-Up

SAME AS PAGE 1

Patient Number: _

	-		
site #		notient 4	

Patient Initials: ___ ___

Minnesota Living with Heart Failure

Instructions: These questions concern how your heart failure (heart condition) has prevented you from living as you wanted during the last month. The items listed below describe different ways some people are affected. If you are sure an item does not apply to you or is not related to your heart failure then circle 0 (meaning "No") and go onto the next item. If an item does apply to you, then circle the number rating of how much it prevented you from living as you wanted. Remember to think about ONLY THE LAST MONTH.

LWHFQUES (TYPE 3)

Did your heart failure prevent you from living as you wanted during the LAST MONTH by:

	No	Very Little			->	Very Much
1. causing swelling in your ankles, legs, etc?	0	1	2	3	4	5
2. making your working around the house or yard difficult?	0	1	2	3	4	5
3. making your relating to or doing things with your friends difficult?	0	1	2	3	4	5
4. making you sit or lie down to rest during the day?	0	1	2	3	4	5
5. making you tired, fatigued, or low on energy?	0	1	2	3	4	5
6. making your working to earn a living difficult?	0	1	2	3	4	5
7. making your walking or climbing stairs difficult?	0	1	2	3	4	5
8. making you short of breath?	0	1	2	3	4	5
9. making your sleeping well at night difficult?	0	1	2	3	4	5
10. making you eat less of the foods you like?	0	1	2	3	4	5
11. making your going places away from home difficult?	0	1	2	3	4	5
12. making your sexual activities difficult?	0	1	2	3	4	5
13. making your recreational pastimes, sports, or hobbies difficult?	0	1	2	3	4	5
14. making it difficult for you to concentrate or remember things?	0	1	2	3	4	5
15. giving you side effects from medications?	0	1	2	3	4	5
16. making you worry?	0	1	2	3	4	5
17. making you feel depressed?	0	1	2	3	4	5
18. costing you money for medical care?	0	1	2	3	4	5
19. making you feel a loss of self-control in your life?	0	1	2	3	4	5
20. making you stay in a hospital?	0	1	2	3	4	5
21. making you feel you are a burden to your family or friends?	0	1	2	3	4	5



3-Month Follow-Up

Patient Number: _____ - ___ Patient Initials: _____

Contact Status		
Date of contact:/	/SAME AS PAGE 33	CONTACT (TYPE 3)
day ma	nth year	
Mode of contact (check only one):	Clinic visit	
	Telephone call	
	Rehospitalization	
	Continuous hospitalization since randomization	
	□ Lost to follow-up→ Date of last contact:/	_/
	Other (specify):	<u> </u>
Resuscitation Orders		
Resuscitation orders (check only one):	Attempt cardiopulmonary resuscitation	
	Attempt cardiopulmonary resuscitation but do not intubate	
	Do not attempt cardiopulmonary resuscitation	
	CIP this box for patients with a continuous hospitalization since rando	
NoYes → If Yes, number of	Imitted to the hospital or emergency department for more than 2 times:he Rehospitalization Form (insert page) for each hospital admissi	
□ No	dergone a cardiovascular operation or procedure (e.g., CABG, P	AC, mechanical ventilation)?
Since the last visit has the patient die	ed?	
□ No → If No, transplant s		
	☐ Ineligible	
	☐ Active evaluation	
	☐ Listed	,
	Received transplant → Date:/	
	 Accepted, but waiting to determine need after disch Not evaluated 	arge
\square Yes \rightarrow If Yes, complete p	page 70, Event Notification Form and the Death Form (insert page	e)



3-Month Physician Assessment

Patient Number: Patient Initials: patient # **Heart Failure Clinical Assessment—Symptoms** SYMPTOMS (TYPE 3) Does the patient have any of the following? No Yes Yes Dyspnea: Fatigue: П \Box At rest At rest Walking in room Any activity Walking < 1 block Routine daily activity Orthopnea (check only one): ■ Needs only 1 pillow □ Occasional orthopnea with 1 pillow ■ Needs 2 pillows most of the time ■ Needs 3 pillows most of the time ■ Needs 4 pillows most of the time (sitting up) Gastrointestinal distress (check only one): None Occasional Occasional NYHA classification (check only one): Heart Failure Clinical Assessment—Physical Exam PHYSEXAM (TYPE 3) Heart rate (standing after 3 minutes): Heart rate (supine): ___ _ bpm Blood pressure manual cuff (supine): _____systolic / ____diastolic mmHg Blood pressure manual cuff (standing after 3 minutes): _____ vertolic / _____ diastolic Weight: ___ _ _ . _ _ 🗆 lb 🗆 kg Respiratory rate: ___ breaths/minute Temperature: ___ __ _ _ . __ 🗆 C 🗆 F Jugular venous pulsation (cm above the right atrium): < 8 8-12 12-16 >16 Cannot measure Rales: ☐ None ☐ < 1/3 ☐ 1/3-2/3 ☐ > 2/3 Auscultation: S3: No Yes Estimated P2-PAS: < 40 40-50 51-60 > 60 Hepatomegaly (check only one): Absent 2-4 finger breadths > 4 finger breadths Hepatojugular reflux: No Yes Ascites (check only one): None Trace Moderate Massive Peripheral edema (check only one): 0 0 1+ 2+ 3+ 4+ Extremities (check only one): Cool Lukewarm Warm Valsalva maneuver (check only one): Normal Absent overshoot Square-wave Uncertain OR Not applicable Clinical profile (check only one): Dry/warm Wet/warm Dry/cold Wet/cold Signature (Physician who performed assessment) SIGNATUR (TYPE 4) SAME AS PAGE 3 Investigator's signature: _____ Date performed: _



Patient Number:

patient #

3-Month Follow-Up

Patient Initials: ___ ___

Current Medications ACE1 (TYPE 3) ACE inhibitor: □ No → If No, specify reason (check all that apply): Angioedema, anaphylaxis, neutropenia Cough Hyperkalemia Renal artery stenosis Renal dysfunction Symptomatic hypotension Other adverse events such as taste disturbance, rash, and gastrointestinal upset

ACE2 (TYPE 3) Total daily dose: Yes → If Yes: Benazepril Captopril Enalapril mg Fosinopril Lisinopril Quinapril mg Ramipril Trandolapril Other (specify): _ mg Total daily ANGIODIG (TYPE 3) Angiotensin II antagonist: No ☐ Yes → If Yes: ☐ Candesartan Losartan Valsartan ___ mg Other (specify): _ Digoxin: No ☐ Yes → If Yes, specify total dose and frequency: __ mg QD QOD Other Total daily dose: TYPE 3) No Yes → If Yes: Bumetanide Diuretic: (loop) Ethacrynic acid __ mg Furosemide Torsemide Other (specify): _ Total daily dose: No Yes → If Yes: Diuretic: Amiloride (potassium sparing) Spironolactone _____ mg Triamterene Other (specify): Total daily DIURCCB (TYPE 3) No Yes → If Yes: Diuretic: Chlorothiazide (diuril) (thiazide) Hydrochlorothiazide (HCTZ) Metolazone (zaroxolyn) ___ mg Other (specify): Calcium channel blocker: Total daily dose: No Yes → If Yes: Amlodipine Other (specify): _ mg



3-Month Follow-Up

			Patient Num	nber:	patient #	Patient	Initials:
Current Me	edications (co	nt.)					
Beta blocker:	□ No □ Yes →		Atenolol Bisoprolol Carvedilol			Total daily do	·
			Metoprolol Propranolol Other (specify):				mg mg
Antiarrhythmics:	□ No □ Yes →	► If Yes:	Amiodarone Dofetilide Sotalol Other (specify):			Total daily do	mg mg mg
Nitrates:	□ No □ Yes →	→ If Yes:	☐ Isosorbide dinitro ☐ Isosorbide mono ☐ Topical nitroglyce	onitrate		Total daily do	HYPOT (TYPE 3) se: mg mg mg
Hydralazine:	☐ No ☐ Yes →	If Yes, to					mg
Potassium:	☐ No ☐ Yes →	If Yes, to	otal daily dose:				'
Statins:		□No	Yes	Antide	pressants:	□ No □ Yes	EDS (TYPE 4) PS
Other lipid loweri	ing agents:	☐ No	Yes	Benzod	diazepines:	☐ No ☐ Yes	
Magnesium:		□ No	Yes	Allopur		☐ No ☐ Yes	
Estrogen replacen		□ No	Yes	Colchic		☐ No ☐ Yes	
Testosterone repla	acement therapy:	□ No	Yes	Enoxap		☐ No ☐ Yes	
Insulin:		□ No	Yes	Warfar		☐ No ☐ Yes	
Oral diabetic age	ents:	□ No	Yes	Vitamin		☐ No ☐ Yes	
Aspirin (daily):		□ No	Yes	-	/me Q10:	☐ No ☐ Yes	
Other antiplatelet	agents:	□ No	Yes		antioxidants:	□ No □ Yes	
NSAIDs:		∐ No	∐ Yes	Multi-vi	tamin:	∐ No ∐ Yes	
Thyroid replacem	ent therapy:	∐ No	Yes Yes				
		SAM	IE AS PAGE 36 Current infusion re	ate:	Check box if i	ntermittent: ^{INFO}	USIN (TYPE 4) PS
Amrinone:	\square No \square Yes \rightarrow If	f Yes:	mc	:g/kg/min	☐ Intermittent -	→ #	days/month
Dobutamine:	\square No \square Yes \rightarrow If	f Yes:	mc	:g/kg/min	☐ Intermittent -	→ #	days/month
Dopamine:	\square No \square Yes \rightarrow If	f Yes:	mc	:g/kg/min	☐ Intermittent -	→ #	days/month
Milrinone:	\square No \square Yes \rightarrow If	Yes:	mc	:g/kg/min	☐ Intermittent	→ #	days/month
Nitroglycerin:	\square No \square Yes \rightarrow If	f Yes:	mc	cg/min			
Nitroprusside:	☐ No ☐ Yes → If	f Yes:	mc	cg/min			



3-Month Follow-Up

Patient Number:		Patient Initials:
	site # patient #	

Laboratory			
Date of collection:	/ _{month} / _{year}		LAB (TYPE 4) PS
	Value	Value	
Hemoglobin (Hgb)	9/qΓ □ mmol/Γ □ 8/Γ	AST/SGOT	_ IU/LORU/LOR ^{MIU} /mL
Platelets	10 ^{9/} OR 10 ^{3/} mm ³	Total protein	- □9/L
Hematocrit (Hct)	□ L/L □%	Albumin	- □9/dL □9/L
WBC	10 ⁹ / _L OR 10 ³ / _{mm} 3	Total bilirubin	□ μmol/Γ
Sodium	mmol/L OR mEq/L	Direct bilirubin	_ □ mg/dL □ μmol/L
Potassium	mmol/L OR mEq/L	CK (ULN =)	ENZYMES (TYPE 3) U/L OR U/L OR mIU/mL
BUN	^{mg} / _{dL}	CK-MB (ULN =) □ Not Done	$ = \begin{array}{c} \begin{array}{c} & \text{mcg}/_{\text{L}} \text{ or } ^{\text{Hg}}/_{\text{L}} \text{ or } ^{\text{ng}}/_{\text{mL}} \\ & \text{OR } ^{\text{U}}/_{\text{L}} \text{ or } ^{\text{mlU}}/_{\text{mL}} \\ & \end{array} $
Creatinine	^{mg} / _{dL}	Troponin □ I □ T) □ Not Done	_ ^{ng} / _{mL} or □ Positive □ Negative
ALT/SGPT	IU/LORU/LORMIU/mL		



Patient Number:

patient #

3-Month Follow-Up

Patient Initials:

Visual Analog Scale Scores (Complete the Visual Analog Scale Worksheet insert pages) VISUAL (TYPE 3) Examination date: Worst symptom: ___ _ → Corresponding to (check only one): ☐ Abdominal discomfort Breathing ■ Body swelling Fatigue ___ _ OR Not applicable if breathing was selected as worst symptom Breathing: Global: Time Trade-Off Scores TIMETRAD (TYPE 3) Examination date: or 1 day _ ___ months **6-Minute Walk Exercise Test** Did the patient attempt the 6-minute walk test? WALK (TYPE 3) \square No \rightarrow If No, specify primary reason: ☐ The patient was too critically ill to be taken out of bed and exercised. Patient cannot walk for technical reasons (e.g., a patient who is an amputee). Not done due to oversight. ☐ Yes → If Yes, complete below. Examination date: Start time of walk: End time of walk: Did the patient experience any of the following symptoms (check all that apply): ☐ Angina Light headedness Syncope Borg Dyspnea score: ______ (Transcribe score from worksheet.)



Patient Number:

3-Month Follow-Up

Patient Initials: ___ ___

patient # Echocardiogram Data ECHO (TYPE 3) Send ECHO tape to Brigham Core Lab Cardiopulmonary Exercise (CPX) CPX (TYPE 3) Did the patient attempt cardiopulmonary exercise testing? \square No \rightarrow If No, specify primary reason: ☐ The patient was too critically ill to be taken out of bed and exercised. The patient was unable to walk > 50 meters on the 6 minute walk. Patient cannot walk for technical reasons (e.g., a patient who is an amputee). Not done due to oversight. Yes → If Yes, complete below. Type of exercise (patient should perform same type of exercise throughout study): ☐ Bicycle ☐ Treadmill Peak cardiovascular responses: VO₂ (ml/kg/min): VCO2 (ml/kg/min): VE max (L/min): VE/VCO2 (25 watts or end of first workload on treadmill) VO2 @ R = 1.0: Heart rate (bpm): Systolic BP (max): Diastolic BP (max): Duration of exercise (min): Respiratory exchange ratio: Reason for termination of testing (check primary reason): Patient completed testing Symptom limited (e.g., dyspnea, fatigue) ☐ Angina Serious arrhythmia ■ Blood pressure changes ☐ No longer able to walk (e.g., leg cramps) Other



3-Month Follow-Up

Patient Initials: ___ ___

Patient Number: _____site # patient # **Follow-Up Summary** FOLLOW (TYPE 3) Follow-Up Instructions for Sodium and Fluid Restriction: SAME AS PAGE 38 Sodium restriction: ____ mg/day _____ L/day Fluid restriction: Was the patient given a diuretic plan for weight gain? ☐ No ☐ Yes → If Yes, for every 2 lb weight gain patient: (check all that apply) Increases loop diuretics Adds thiazide/metolazone Nurse/Study Coordinator Estimate of Likelihood of Death over next 6 months Check only one: 0-25% 26-50% THIS NOT ENTERED 51-75% 76-100% Nurse/Study Coordinator Estimate of Readmission over next 6 months Check only one: 0-25% 26-50% THIS NOT ENTERED 76-100% Signature SAME AS PAGE 3

The data recorded on CRF pages 53-61 have been reviewed by me or my delegate and are accurate and complete to the best of my knowledge. Investigator's signature: ____



STUDYBOOK=ESCAPE FORM=6-MONTH FOLLOW-UP

Patient Number:

6-Month Follow-Up

SAME AS PAGE 1

		Patient Initials
site#	patient #	

Minnesota Living with Heart Failure

Instructions: These questions concern how your heart failure (heart condition) has prevented you from living as you wanted during the last month. The items listed below describe different ways some people are affected. If you are sure an item does not apply to you or is not related to your heart failure then circle 0 (meaning "No") and go onto the next item. If an item does apply to you, then circle the number rating of how much it prevented you from living as you wanted. Remember to think about ONLY THE LAST MONTH.

LWHFQUES (TYPE 3)

Did your heart failure prevent you from living as you wanted during the LAST MONTH by:

	No	Very Little			→	Very Much
1. causing swelling in your ankles, legs, etc?	0	1	2	3	4	5
2. making your working around the house or yard difficult?	0	1	2	3	4	5
3. making your relating to or doing things with your friends difficult?	0	1	2	3	4	5
4. making you sit or lie down to rest during the day?	0	1	2	3	4	5
5. making you tired, fatigued, or low on energy?	0	1	2	3	4	5
6. making your working to earn a living difficult?	0	1	2	3	4	5
7. making your walking or climbing stairs difficult?	0	1	2	3	4	5
8. making you short of breath?	0	1	2	3	4	5
9. making your sleeping well at night difficult?	0	1	2	3	4	5
10. making you eat less of the foods you like?	0	1	2	3	4	5
11. making your going places away from home difficult?	0	1	2	3	4	5
12. making your sexual activities difficult?	0	1	2	3	4	5
13. making your recreational pastimes, sports, or hobbies difficult?	0	1	2	3	4	5
14. making it difficult for you to concentrate or remember things?	0	1	2	3	4	5
15. giving you side effects from medications?	0	1	2	3	4	5
16. making you worry?	0	1	2	3	4	5
17. making you feel depressed?	0	1	2	3	4	5
18. costing you money for medical care?	0	1	2	3	4	5
19. making you feel a loss of self-control in your life?	0	1	2	3	4	5
20. making you stay in a hospital?	0	1	2	3	4	5
21. making you feel you are a burden to your family or friends?	0	1	2	3	4	5



6-Month Follow-Up

Patient Number: _____ - ____ Patient Initials: ______

Contact Status		
Date of contact:/	SAME AS PAGE 33	CONTACT (TYPE 3)
day mo	nth year	
Mode of contact (check only one):	Clinic visit	
	☐ Telephone call	
	Rehospitalization	
	Continuous hospitalization since randomization	
	□ Lost to follow-up→ Date of last contact:/	
	Other (specify):	
Resuscitation Orders		
Resuscitation orders (check only one):	Attempt cardiopulmonary resuscitation	
-	Attempt cardiopulmonary resuscitation but do not intubate	
	Do not attempt cardiopulmonary resuscitation	
Endpoint Summary (SK	(IP this box for patients with a continuous hospitalization since rar	idomization.)
NoYes → If Yes, number of	Imitted to the hospital or emergency department for more the times:has been department for more the times: has been department for more the times has been department for more the first page for each hospital administration form (insert page) for each hospital administration form (insert page) for each hospital administration for more than the first page for each hospital administration for more than the first page for each hospital administration for more than the first page for each hospital administration for more than the first page for each hospital administration for more than the first page for each hospital administration for more than the first page for each hospital administration for more than the first page for each hospital administration for more than the first page for each hospital administration for each each each each each each each each	
□ No	dergone a cardiovascular operation or procedure (e.g., CABC	3, PAC, mechanical ventilation)?
Since the last visit has the patient die	ed?	
□ No → If No, transplant s	status (check only one):	
	☐ Ineligible	
	☐ Active evaluation	
	☐ Listed	,
	☐ Received transplant → Date:/	,
	 Accepted, but waiting to determine need after d Not evaluated 	ischarge
\square Yes \rightarrow If Yes, complete p	age 70, Event Notification Form and the Death Form (insert p	page)



6-Month Physician Assessment

Patient Initials:

Patient Number: _ Heart Failure Clinical Assessment – Symptoms SYMPTOMS (TYPE3) Does the patient have any of the following? No Yes Yes Dyspnea: Fatigue: At rest At rest \Box Walking in room Any activity Walking < 1 block Routine daily activity ☐ Needs only 1 pillow Orthopnea (check only one): Occasional orthopnea with 1 pillow Needs 2 pillows most of the time ☐ Needs 3 pillows most of the time ☐ Needs 4 pillows most of the time (sitting up) Gastrointestinal distress (check only one): None Occasional Occasional NYHA classification (check only one): Heart Failure Clinical Assessment – Physical Exam PHYSEXAM (TYPE 3) Heart rate (standing after 3 minutes): _____ Heart rate (supine): ___ __ bpm Blood pressure manual cuff (supine): _____systolic / _____diastolic mmHg Blood pressure manual cuff (standing after 3 minutes): ______ / ____ diastolic mmHg Weight: ___ __ . __ 🗆 lb 🔲 kg Respiratory rate: ___ breaths/minute Temperature: ___ _ _ _ _ _ _ _ _ _ C _ _ F Jugular venous pulsation (cm above the right atrium): < 8 8 8 - 12 12 - 16 > 16 Cannot measure Rales: ☐ None ☐ < 1/3 ☐ 1/3-2/3 ☐ > 2/3 Auscultation: S3: No Yes Estimated P2-PAS: < 40 40-50 51-60 > 60 Hepatomegaly (check only one): ☐ Absent ☐ 2-4 finger breadths ☐ > 4 finger breadths Hepatojugular reflux: No Yes Ascites (check only one): None Trace Moderate Massive Peripheral edema (check only one): 0 0 1+ 2+ 3+ 4+ Extremities (check only one): Cool Lukewarm Warm Valsalva maneuver (check only one): Normal Absent overshoot Square-wave Uncertain OR Not applicable Clinical profile (check only one): Dry/warm Wet/warm Dry/cold Wet/cold Signature (Physician who performed assessment) SAME AS PAGE 3 SIGNATUR (TYPE 4) Investigator's signature: ______ Date performed: _



6-Month Follow-Up

Patient Number: _____ - ____ Patient Initials: ___ ___

Current Mo	edicalions		
ACE inhibitor:	□ No → If No, specify red	ason (check all that apply):	ACE1 (TYPE 3)
	, ., ., ., .,	Angioedema, anaphylaxis, neutropenia	
		☐ Cough	
		☐ Hyperkalemia	
		Renal artery stenosis	
		Renal dysfunction	
		Symptomatic hypotension	
		Other adverse events such as taste disturbance,	rash, and gastrointestinal upset — ACE2 (TYPE 3)
			Total daily dose:
	Yes → If Yes:	Benazepril	mg
		☐ Captopril	mg
		☐ Enalapril	mg
		Fosinopril	mg
		Lisinopril	mg
		Quinapril	mg
		Ramipril	mg
		☐ Trandolapril	mg
		Other (specify):	mg
Angiotensin II anto	agonist:		ANGIODIG (TYPE 3) Total daily dose:
	No Yes → If Yes:	☐ Candesartan	mg
		Losartan	mg
		☐ Valsartan	mg
		Other (specify):	mg
Digoxin:	No Yes → If Yes,		
Digoxin:	□ No □ Yes → If Yes,	specify total dose and frequency:	mg QD
Digoxin:	□ No □ Yes → If Yes,		mg QD QOD Other
Digoxin:	 No		mg QD QOD Other
		specify total dose and frequency:	mg QD QOD Other Total daily dose: Total daily dose:
Diuretic:		specify total dose and frequency:	mg QD QOD Other Total daily dose: mg
Diuretic:		Bumetanide Ethacrynic acid	mg QD QOD Other Total daily dose: mg mg
Diuretic:		Bumetanide Ethacrynic acid Furosemide	mg QD QOD Other Total daily dose: mg mg mg or mg mg mg mg
Diuretic:		Bumetanide Ethacrynic acid Furosemide Torsemide	mg
Diuretic:		Bumetanide Ethacrynic acid Furosemide Torsemide	mg QD QOD Other Total daily dose: mg mg mg mg mg mg mg mg
Diuretic: (loop)	No Yes → If Yes:No Yes → If Yes:	Bumetanide Ethacrynic acid Furosemide Torsemide Other (specify):	mg
Diuretic: (loop)	No Yes → If Yes:No Yes → If Yes:	Bumetanide Ethacrynic acid Furosemide Torsemide Other (specify): Amiloride Spironolactone Triamterene	mg
Diuretic: (loop)	No Yes → If Yes:No Yes → If Yes:	Bumetanide Ethacrynic acid Furosemide Torsemide Other (specify): Amiloride Spironolactone	mg
Diuretic: (loop)	No Yes → If Yes:No Yes → If Yes:	Bumetanide Ethacrynic acid Furosemide Torsemide Other (specify): Amiloride Spironolactone Triamterene	mg QD QOD Other Total daily dose: mg
Diuretic: (loop) Diuretic: (potassium sparing	No Yes → If Yes:No Yes → If Yes:	Bumetanide Ethacrynic acid Furosemide Other (specify): Amiloride Spironolactone Triamterene Other (specify):	mgmgmg
Diuretic: (loop) Diuretic: (potassium sparing	 No Yes → If Yes: No Yes → If Yes: g) 	Bumetanide Ethacrynic acid Furosemide Other (specify): Amiloride Spironolactone Triamterene Other (specify): Chlorothiazide (diuril) Hydrochlorothiazide (HCTZ)	mg QD QOD Other Total daily dose: mg
Diuretic: (loop) Diuretic: (potassium sparing	 No Yes → If Yes: No Yes → If Yes: g) 	Bumetanide Ethacrynic acid Furosemide Torsemide Other (specify): Amiloride Spironolactone Triamterene Other (specify): Chlorothiazide (diuril) Hydrochlorothiazide (HCTZ) Metolazone (zaroxolyn)	mg QD QOD Other Total daily dose: mg Total daily dose: mg mg mg Total daily dose: mg
Diuretic: (loop) Diuretic: (potassium sparing)	 No Yes → If Yes: No Yes → If Yes: g) 	Bumetanide Ethacrynic acid Furosemide Other (specify): Amiloride Spironolactone Triamterene Other (specify): Chlorothiazide (diuril) Hydrochlorothiazide (HCTZ)	mg QD QOD Other Total daily dose:
Diuretic: (loop) Diuretic: (potassium sparing)	 No	Bumetanide Ethacrynic acid Furosemide Torsemide Other (specify): Amiloride Spironolactone Triamterene Other (specify): Chlorothiazide (diuril) Hydrochlorothiazide (HCTZ) Metolazone (zaroxolyn)	mg
Diuretic: (loop) Diuretic: (potassium sparing) Diuretic: (thiazide)	 No	Bumetanide Ethacrynic acid Furosemide Torsemide Other (specify): Amiloride Spironolactone Triamterene Other (specify): Chlorothiazide (diuril) Hydrochlorothiazide (HCTZ) Metolazone (zaroxolyn)	mg



Patient Number: ___ - __ -__ __

6-Month Follow-Up

Patient Initials: ___ ___

				site #	patient #	
Current M	edications (co	nt.)				
Beta blocker:	□ No □ Yes →	If Yes:	Atenolol Bisoprolol Carvedilol Metoprolol Propranolol Other (specify)	l:		Total daily dose: mg mg mg mg mg mg mg mg mg
Antiarrhythmics	: □ No □ Yes →	• If Yes:	Amiodarone Dofetilide Sotalol Other (specify,):		Total daily dose: mg mg mg mg
Nitrates:	□ No □ Yes →	• If Yes:	☐ Isosorbide di ☐ Isosorbide m ☐ Topical nitrog	ononitrate		Total daily dose: mg mg mg
Hydralazine:	☐ No ☐ Yes →	If Yes, to	otal daily dose:			mg
Potassium:	☐ No ☐ Yes →	If Yes, to	otal daily dose:			mEq
Statins:		□No	Yes	Antidepr	essants:	□ No □ Yes (TYPE 4) PS
Other lipid lowe	ring agents:	☐ No	Yes	Benzodio	azepines:	☐ No ☐ Yes
Magnesium:		□No	Yes	Allopurir	•	□ No □ Yes
Estrogen replace	ement therapy:	□No	Yes	Colchicin		□ No □ Yes
_	placement therapy:	□No	Yes	Enoxapa	ırin:	□ No □ Yes
Insulin:	,,,	□No	Yes	Warfarir		□ No □ Yes
Oral diabetic ag	ents:	□No	Yes	Vitamin	E:	□ No □ Yes
Aspirin (daily):	,	□ No	Yes	CoEnzyn	ne Q10:	□ No □ Yes
Other antiplatel	et agents:	□No	Yes		ntioxidants:	□ No □ Yes
NSAIDs:	·	□ No	Yes	Multi-vita	amin:	□ No □ Yes
Thyroid replace	ment therapy:	□No	Yes			
	S	SAME A	S PAGE 36. Current infusion	n rate:	Check box if i	ntermittent: INFUSIN (TYPE 4) PS
Amrinone:	□ No □ Yes → If	Yes:		mcg/kg/min		→ # days/month
Dobutamine:	□ No □ Yes → If	Yes:		mca/ka/min	_	→ # days/month
Dopamine:	□ No □ Yes → If					→ # days/month
Milrinone:	□ No □ Yes → If					→ # days/month
Nitroglycerin:	No Yes → If			mcg/min		50/10/110/110
Nitroprusside:	□ No □ Yes → If			mcg/min		
				-0/		



6-Month Follow-Up

Patient Number:	 patient #	Patient Initials:

Laboratory			
Date of collection:	/ _{month} / _{year}		LAB (TYPE 4) PS
	Value	Value	
Hemoglobin (Hgb)	□ 9/L □ mmol/L □ 9/dL	AST/SGOT	_ ^{IU} / _L or ^U / _L or ^{mIU} / _{mL}
Platelets	\Bigcup 10 ⁹ / _L or 10 ³ / _{mm} 3 \Bigcup / _{mm} 3	Total protein	□ a\ ^Γ □ □ a\qr
Hematocrit (Hct)	□ L/L □ %	Albumin	_ □ a\ ^Γ _ □ a\qr
WBC		Total bilirubin	_ □ mg/ _{dL} □ μmol/ _L
Sodium	mmol/L OR mEq/L	Direct bilirubin	_ □ ^{mg} / _{dL} □ μ ^{mol} / _L
Potassium	mmol/L OR mEq/L	CK (ULN =)	_ IU/L OR UZYMES (TYPE 3)
BUN	^{mg} / _{dL}	CK-MB (ULN =) □ Not Done	$\begin{array}{c c} & \operatorname{mcg/_LOR} ^{\operatorname{Hg}/_LOR} ^{\operatorname{ng}/_{\operatorname{mL}}} \\ & \operatorname{\square} ^{\operatorname{IU}/_LOR} ^{\operatorname{U}/_LOR} ^{\operatorname{mlU}/_{\operatorname{mL}}} \\ & \end{array}$
Creatinine	^{mg} / _{dL}	Troponin □ I □ T) □ Not Done	_ ^{ng} / _{mL} or □ Positive □ Negative
ALT/SGPT	IU/L OR U/L OR MIU/mL		



6-Month Follow-Up

Patient Initials: ___ ___

Patient Number: _____ - ____patient # Visual Analog Scale Scores (Complete the Visual Analog Scale Worksheet insert pages) VISUAL (TYPE 3) Worst symptom: ___ _ _ → Corresponding to (check only one): ☐ Abdominal discomfort Breathing ■ Body swelling Fatigue ___ _ OR Not applicable if breathing was selected as worst symptom Global: **Time Trade-Off Scores** TIMETRAD (TYPE 3) or 1 day Score: _ ___ months **6-Minute Walk Exercise Test** WALK (TYPE 3) Did the patient attempt the 6-minute walk test? No → If No, specify primary reason: The patient was too critically ill to be taken out of bed and exercised. Patient cannot walk for technical reasons (e.g., a patient who is an amputee). Not done due to oversight. Yes → If Yes, complete below. Examination date: Start time of walk: End time of walk: Did the patient experience any of the following symptoms (check all that apply): ☐ Angina Light headedness Syncope Borg Dyspnea score: ______ (Transcribe score from worksheet.)



6-Month Follow-Up

	Patie	ent Number:	patient #	Patient Initials:
		211d #	patient #	
Follow-Up Su	ımmary			
Follow-Up Instructions	for Sodium and Fluid Restriction: S	SAME AS PAGE 38		FOLLOW (TYPE 3)
Sodium restriction:	mg/day			
Fluid restriction:	L/day			
Was the patient given	a diuretic plan for weight gain?		, for every 2 lb wei all that apply)	ght gain patient:
		☐ Inc	creases loop diuretics	}
		☐ Ad	lds thiazide/metolaz	one.
Nurse/Study	Coordinator Estimate	of Likelihood	of Death o	ver next 6 months
Check only one:	□ 0-25% □ 26-50% □ 51-75% □ 76-100%			THIS NOT ENTERED
Nurse/Study	Coordinator Estimate	of Readmissi	on over nex	t 6 months
Check only one:	□ 0-25% □ 26-50% □ 51-75% □ 76-100%			THIS NOT ENTERED
Signature				
The data recorded on CRF p	SAME As ages 62–70 have been reviewed by me or my	S PAGE 3 delegate and are accurate of	and complete to the best	SIGNATUR (TYPE 4) of my knowledge.
Investigator's signatur	re:	Dat	te:/ _{mo}	/

Complete and submit the Early Withdrawl/Study Completion page 70.



STUDYBOOK=ESCAPE FORM=EARLY WITHDRAWAI Early Withdrawal/Study Completion

Patient Number: ____ - ____ Patient Initials: ___ ___

	,	te #	patient #	
Early Withdrawal/Stu	dy Completion			
Date patient ended the study:	STYCOMDT <date></date>			STDYCOMP (TYPE 1)
Did the patient complete the study? COMPSTDY <				
\bigcirc No \rightarrow If No, choose	primary reason: NOCOMPRE <escore> Cardiac transplantation</escore>			
	2 Consent withdrawn			
	3 Lost to follow-up			
	4 Protocol violation			
	5 Physician decision			
	6 Early study termination			
Signature				
I have reviewed and found all data pertaining	to this subject to be complete and accurate.			SIGNATUR (TYPE 4)
Responsible investigator's signature	N:	_ Date:	/ _{mont}	mh/
Study coordinator's signature:		_ Date:	/ mont	th/



0 No

STUDYBOOK=ESCAPE FORM=REHOSPITALIZATION

Rehospitalization Form

Patient Initials: _ Patient Number: patient # Rehospitalization Form (Patient readmitted to hospital OR in emergency department > 24 hours.) day / HSPADMDT <DATE> Date of admission: REHOSP1 (TYPE 3) HSPDISDT < DATE> Date of discharge: REHOSP2 (TYPE 3) Primary reason for rehospitalization (check only one): Secondary reason for rehospitalization (check all that apply): HOSPRE <ESHSRE> HRTFAIL <ZYES> Heart failure exacerbation → Complete CHF Form 1 Heart failure exacerbation ACCORSYN < ZYES> Acute coronary syndrome (check only one): ACUTETYP <ESSYN>

Myocardial infarction 2 Unstable angina Unstable angina 3 Chest pain unspecified 3 Chest pain unspecified OTHRCAR <ZYES>
Other cardiovascular (check only one): 3 Other cardiovascular (check only one): OTHCARS <ESOTHC>

☐ Procedure related → Complete CV Procedures/ OTHCAR <ESOTHC>
Complete CV Procedures/ Mechanical Ventilation Form Mechanical Ventilation Form 2 Stroke 2 Stroke 3 Transient ischemic attack 3 Transient ischemic attack 4 Pulmonary embolism 4 Pulmonary embolism 98 Other 98 Other 4 Arrhythmia (check only one):

ARRH < ESARRH >

Sudden death with resuscitation ARRYTH <ZYES>
Arrhythmia (check only one): ARRYH < ESARRH> 1 Sudden death with resuscitation 2 Supraventricular arrhythmia 2 Supraventricular arrhythmia 3 Ventricular arrhythmia 3 Ventricular arrhythmia 4 ICD firing 4 ICD firing 5 AV block 3 AV block 6 Syncope 6 Syncope CANCER < ZYES> 5 Cancer 1 Cancer Non-cardiovascular Non-cardiovascular 6 Non-cardiovascular UNDETR <ZYES> 7 Unable to determine 1 Unable to determine CV Procedures/Mechanical Ventilation Did the patient undergo any cardiovascular procedures during the rehospitalization? REHOSP3 (TYPE 3) CARPROC <ZYESNO>

1 Yes → If Yes, Complete page D of the CRF

26 January 2000 Version 3.0



STUDYBOOK=ESCAPE FORM=CHF FORM

CHF Form

Patient Initials: ___ __ Patient Number: site # patient # CHF Form (To be completed if worsening CHF was the reason for hospitalization.) CHF (TYPE 3) Date of CHF exacerbation: What evidence was there of worsening CHF (check all that apply): FATWRS <ZYES>
Worsening/increasing fatigue
DYSP <ZYES> Dyspnea Orthopned <ZYES> GIDISST <ZYES>
I Gastrointestinal distress
ELVATIVP <ZYES>
I Elevated JVP PEDEMA <ZYES>
Peripheral edema
ASHEPRFL <ZYES>
Ascites/hepatomegaly/hepatojugular reflux Renal hypoperfusion/worsening renal function TXIVDIU <ZYESNO> No 1 Yes Was the patient treated with intravenous diuretics? TXIVINO <ZYESNO> Was the patient treated with intravenous inotropic agents? 0 No 1 Yes TXIVVAS <ZYESNO> Was the patient treated with an intravenous vasodilator? No 1 Yes



STUDYBOOK=ESCAPE FORM=MI FORM

MI Form

Patient Number: _____ Patient Initials: _____

MI Form		
Was the clinical presentation consistent with	MIDT <date> /</date>	MITM < DATETIME> MI1 (TYPE 3 00:00 to 23:59
	Yes → If Yes, check all that apply:	 New Q-wave NQWAVE <zyes></zyes> New left bundle branch block NLBBB <zyes></zyes> ST ↑ (> 1.0 mm) ≥ 2 leads STINC <zyes></zyes> ST ↓ (> 1.0 mm) ≥ 2 leads STDEC <zyes></zyes> T wave inversion TWAVE <zyes></zyes> G with the most significant changes.
Peak CK: PKCKDT < DATE >	< <u>F:9:3></u>	
Value: < <u>F:9:3</u> > ☐ mcg/	PKCMBTN PKCMBULN F:9:3> KCMBUNT <eslunt></eslunt>	MI2 (TYPE 3)
Peak Troponin: PKTROPDT <date <estro="" day="" month="" pktrotyp=""> I OR D=T Upper limit of normal = PKTROVAL Value: <f:9:3> ng/mL</f:9:3></date>	PKTROULN <f:9:3> PKTROPN < ZPOSNE></f:9:3>	M <datetime></datetime>



STUDYBOOK=ESCAPE

Patient Number:

FORM=CV PROCEDURES FORM CV Procedures/Mechanical

Patient Initials: ___ ___

CV Procedures/Mechanical Ventilation Form SAME AS PAGE 19
Were any of the following procedures performed? Answer ALL questions; Yes or No. PROC (TYPE 4) PS No Yes → If Yes, date: Pulmonary artery catheterization Left heart catheterization PTCI П CABG day month year ICD implantation day month year П Permanent pacemaker day / -- month / -- year П Temporary pacemaker Left ventricular assist device Intra-aortic balloon pump Cardiopulmonary resuscitation Cardioversion Other cardiovascular procedure/operation MECHVENT <ZYESNO> PROCMV (TYPE 4) Mechanical ventilation INTUBDT <DATE> 1 Yes \rightarrow If Yes, date of intubation: $\frac{1}{1}$ Yes $\frac{$ → If Yes, date of extubation: EXTUBDT < DATE > year year



STUDYBOOK=ESCAPE FORM=DEATH FORM

Patient Number: _____ Patient Initials: _____

Death Form		
Date of death:/DTHDT <date></date>	ear,	DEATH (TYPE 3)
Primary cause of death (check only one): DTHCAUS < ESDTH COMPLETE CHE Form if death (check only one): OTHER CAUSE COMPLETE CHE FORM IT DESCRIPTION OF THE CHECK	ath occurred after index hospitalization	
☐ Fatal myocardial infarction → Complete MI	Form	
3 Unexpected "sudden death" (check only one):	SUDNDTH <essudn> I Identified arrhythmia Witnessed cardiac arrest Unwitnessed cardiac arrest Sudden death associated with unexpected worsening of he</essudn>	eart failure
4 Other cardiovascular (check only one):	e CV Procedures/Mechanical Ventilation Form occurred after index hospitalization	
2 Stroke		
4 Pulmonary embolism		
Other		
5 Cancer		
6 Non-cardiovascular death		
7 Unable to determine		

Send a copy of the Discharge Summary and/or Autopsy Report



Event Notification Form

Patient Number:	cito# nations#	Patient Initials:
-----------------	----------------	-------------------

Complete this form for ALL:

- Deaths;
- PAC-associated pulmonary infarction/hemorrhage; and
- PAC-associated complications requiring cardiopulmonary resuscitation.

Event Notification Form
Date completed: / _{month} / _{year} → (Date Example: 12/OCT/1930)
Sex: Female Male
Date of birth:/
Did the patient die? ☐ No ☐ Yes→ If Yes, date of death:/
→ If Yes, complete the Death Form (page E) of the Case Report Form (CRF). (Note: DO NOT FAX the Death Form page in with this Event Notification Form.)
Did the patient experience a PAC-associated pulmonary infarction/hemorrhage?
No ☐ Yes → If Yes, date of event:
Did the patient experience a PAC-associated complication requiring cardiopulmonary resuscitation?
No ☐ Yes → If Yes, date of event:
→ If Yes, complete the Complications of PAC section on page 15 or 15 of the CRF. (Note: DO NOT FAX the Complications of PAC section in with this Event Notification Form.)
Name of person submitting form (print):
Phone number: ()

FAX this page to the DCRI Safety Desk at (919) 668-7138 within 24 hours.

CALL the DCRI Safety Desk at (919) 668-8624 with any questions.



STUDYBOOK-ESCAPE Physician Estimule of FORM-CROSSOVER FORM Hemodynamic Status—Crossover Form Physician Estimate of

Estimate of Hemodynamic Status	
SAME AS PAGE 3	HEMSTAT (TYPE 3)
Date patient crossed over to PAC placement:/	
Right atrial pressure (mmHg) (check only one):	
Certainty of assessment (check only one): 1 2 3 4 5 not very sure very sure	
Pulmonary capillary wedge pressure (mmHg) (check only one): <pre> < 12</pre> <pre> 12 - 22</pre> <pre> 23 - 30</pre>	<u>>30</u>
Certainty of assessment (check only one): 1 2 3 4 5 not very sure very sure	
Cardiac index (L/min • m²) (check only one):	
Certainty of assessment (check only one): 1 2 3 4 5 not very sure ————————————————————————————————————	



THIS PAGE IS NOT ENTERED Randomization Worksheet

Patient Number:		Patient Initials:
	site # patient #	

The physician must complete the Physician Assessment pages of the CRF prior to randomization.

Demographics (The following 5 questions will be asked during the randomization phone call.)		
Date of birth:		
Race (check one): Caucasian Black Asian Hispanic Native American Other (specify):		_
The Physician's Assessment (estimate) regarding cardiac index (check one): □ ≤ 2.2 □ > 2.2		
Has the written informed consent been obtained? No Yes		
Has the written informed consent been obtained: 140 1es		
Inclusion Criteria (must answer "Yes" to questions 1–11 to be eligible)		
	No	Yes
1 Is the patient ≥ 16 years of age?		
2 Is the patient currently hospitalized under the care of the heart failure service of the investigating site?		
3 Does the patient have NYHA Class IV heart failure symptoms?		
4 Has the patient had one previous hospitalization for exacerbation of heart failure within 6 months prior		
to randomization?		
5 Does the patient have documented LVEF < 30% within 12 months prior to randomization?		
6 Does the patient have a documented history of heart failure for ≥ 3 months?		
7 Has the patient had attempted therapy with angiotensin converting enzyme inhibitors and diuretics for		
≥ 3 months prior to randomization?		
8 Does the patient have a systolic blood pressure of ≤ 125 mmHg?		
9 Does the patient have elevated filling pressures present, indicated by one of the following symptoms?		
 dyspnea (at rest, or in supine position, or immediately upon routine activity within one room); 		
• abdominal discomfort;		
• severe anorexia; or		
• nausea without apparent cause other than hepatosplanchnic congestion		
10 Does the patient have one of the following signs?		
 jugular venous pulsation elevation > 10 cm above the right atrium; 		
• square-wave valsalva response;		
• hepatomegaly, ascites, or edema in absence of other obvious causes; or		
rales greater than 1/3 lung fields It is the patient able to undergo placement of a pulmonary artery catheter within the next 12 hours?		
11 is the patient able to offdergo placement of a politionary affery cameler within the next 12 hours:		

Do Not Send This Form With CRF File this Worksheet with the patient's study files. To randomize a patient call: 1-800-388-9564



Patient Number:

Randomization Worksheet

Patient Initials:

	site # patient #		
Ex	clusion Criteria (must answer "No" to questions 12-33 to be eligible)		
		No	Yes
12	Does the patient have acute decompensation felt by the responsible heart failure physician to require or		
	or be likely to require PAC during the next 24 hours for adequate management (patient to be entered in		
	PAC registry)?		
	Does the patient have an active listing for cardiac transplant?		
	Is mechanical ventilation present or anticipated at the time of randomization?		
15	Is a mechanical circulatory assist device, including intra-aortic balloon pump and left ventricular assist		
	device present or antiapated at the time of randomization?		
	Has the patient received IV milrinone within 48 hours prior to randomization?		
17	Is the patient currently receiving IV dopamine or dobutamine at > 3 mcg/kg/min OR has the patient		
	received IV dopamine or dobutamine for > 24 hours prior to randomization?	Ш	
18	Has the patient had an acute myocardial infarction or cardiac surgery within the last 6 weeks before randomization?		
19	Is the patient currently hospitalized for acute coronary syndrome, including acute MI or unstable angina?		
	Does the patient have documented moderate to severe mitral stenosis or aortic stenosis?		
l	Is there a revascularization procedure planned during this hospitalization?		
l	Is there a surgical procedure planned during this hospitalization?		
	Does the patient have documented primary pulmonary hypertension?		
l	Has the patient had a pulmonary infarct within one month before randomization?		
	Does the patient currently have pneumothorax?		
	Does the patient currently have a serum creatinine > 3.5 mg/dL?		
	Does the patient have a temperature > 37.8 degrees Celsius?		
	Does the patient have a WBC count > 13,000 mm ³ ?		
	Does the patient have an exacerbation of heart failure due to a primary factor requiring specific therapy		
	such as severe anemia, clinical hypothyroidism, or active systemic infection?		
30	Does the patient have any non-cardiac disease, such as cancer, that is likely to shorten life expectancy		
	to < 1 year?		
31	Is the patient unable to return to the heart failure program at the investigating site for all follow-up visits?		
32	Is the patient a female who is pregnant or lactating (Note: All females of childbearing potential should have a negative		
	pregnancy test prior to randomization)?		
33	Is the patient a female of child bearing potential who is not using an accepted method of birth control?		
Ra	andomization		
If th	ne patient is eligible for ESCAPE, please call 1-800-388-9564 AND access code 856 .		
Assi	igned patient number:		
Assi	igned treatment allocation (check one): Pulmonary artery catheter Clinical assessment		
	• • • • • • •		
Kuli	adomization date and time:/		
Siç	gnature		
Sigr	nature:		

Complete the Visual Analog Scales, Minnesota Living with Heart Failure, Time Tradeoff, echocardiogram, cardiopulmonary exercise test, and the 6-minute walk **prior** to PAC placement **OR** clinical therapy.



Patient Number:		
	site #	patient #

t Initials:
t Initials:

Patient Contact Info	ormation (Please Print)		
Patient Identification			
Hospital name:			
Patient name:	last 'First Middle		
Social security number/			
	Medical record number:		
Primary home address:			
-			
-			
-			
Primary home phone number:	Best time to call:		☐ PM
Business phone number:	Best time to call:		□ PM
Spouse or significant other:	last First	Middle	
Secondary Residence (vacat	tion home, etc.)		
Mailing address:			
-			
-			
Phone number:	Best time to call:		
Alternative Contact (relative	, friend or neighbor not living with patient)		
Name:last	, First Middle		
Relationship to patient:			
Mailing address:			
-			
-			
Phone number:	Best time to call:		
Local/Referring Physician	or Primary Care Physician/General Practitioner		
Name:last	, First Middle		
Mailing address:	rii si middie		
_			
_			
Physician's office phone numbe	er:		

Contains Confidential Patient Information

Do not FAX or send this page to Coordinating Center



ESCAPE Visual Analog Scale Worksheet—Worst Symptom

Patient Number: site # patient #	Patient Initials	s:
Date of Evaluation: $\phantom{aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa$	/	
Check One: Baseline Discharge	2-Week Follow-up	1-Month Follow-up


Patient Visual Analog Scale—Worst Symptom (use the same worst symptom each time) **Directions:** 100 Best imaginable: Patient feels comfortable Which of the following bothers you the most? and normal throughout the day. (check only one): Abdominal discomfort ☐ Breathing 90 □ Body swelling ☐ Fatigue 80 50 40 30 20 10 Worst imaginable: Symptom is the most severe the patient can imagine.

05/28/2004



Visual Analog Scale Worksheet—Breathing


Patient number: patient #	Patient Initials:
Date of evaluation:/	h
9	☐ 2 Week Follow-Up ☐ 1 Month Follow-Up MonthFollow-Up ☐ 6 Month Follow-Up





Visual Analog Scale Worksheet—Global

Patient Num	ber: patient #	Patient Initials:
Date of Eval	uation:/ / _{month} /	year
Check one:	☐ Baseline ☐ Discharge ☐ 2	Week Follow-Up 🔲 1 Month Follow-Up
	☐ 2 Month Follow-Up ☐ 3 Month	hFollow-Up





Screening Log

Site number:	
--------------	--

Refer to the back of this form to obtain the reason(s) the patient was not enrolled into the study and record the corresponding number(s).

Date of Screening	Pt. Initials/ Sex	Race	Registry	Reason not Enrolled/ Comment
			☐ Yes ☐ No	
	F		☐ Yes	
			☐ Yes	
	F		☐ Yes ☐ No	
	F		☐ Yes	
			☐ Yes ☐ No	